

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 February 2003 (06.02.2003)

PCT

(10) International Publication Number
WO 03/010243 A2

(51) International Patent Classification⁷: C09C

(21) International Application Number: PCT/CA02/01130

(22) International Filing Date: 26 July 2002 (26.07.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/916,639 26 July 2001 (26.07.2001) US
09/991,480 9 November 2001 (09.11.2001) US
10/099,539 15 March 2002 (15.03.2002) US

(71) Applicant (for all designated States except US): **MCGILL UNIVERSITY** [CA/CA]; 845 Sherbrooke St., W. Montreal, Quebec H3A 2T5 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **TOMA, Jean** [CA/CA]; 50 Alexander Street, Apt. #2008, Toronto, Ontario M4Y 1B6 (CA). **AKHAVAN, Mahnaz** [CA/CA]; 40 Pleasant Blvd., Apt. #2504, Toronto, Ontario M4T 1J9 (CA). **FERNANDES, Karl, J., L.** [CA/CA]; 214 Woodbine Avenue, Toronto, Ontario M4L 3P2 (CA). **FORTIER, Mathieu** [CA/CA]; 155 de la Grande Coulee, Orford, Quebec J1X 6Z6 (CA). **MILLER, Freda** [CA/CA]; 87 Marlborough Avenue, Toronto, Ontario M5R 1X5 (CA).

(74) Agents: **FRITZ, Joachim, T.** et al.; Borden Ladner Gervais LLP, World Exchange Plaza, 100 Queen Street, Suite 1100, Ottawa, Ontario K1P 1J9 (CA).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MULTIPOTENT STEM CELLS FROM PERIPHERAL TISSUES AND USES THEREOF

(57) Abstract: This invention relates to multipotent stem cells, purified from the peripheral tissue of mammals, and capable of differentiating into neural and non-neural cell types. These stem cells provide an accessible source for autologous transplantation into CNS, PNS, and other damaged tissues.



WO 03/010243 A2

MULTIPOTENT STEM CELLS FROM
PERIPHERAL TISSUES AND USES THEREOF

Background of the Invention

5 The present invention relates to multipotent stem cells (MSCs) purified from peripheral tissues including peripheral tissues containing sensory receptors such as skin, olfactory epithelium, mucosa, and tongue. The invention also relates to cells differentiated from these multipotent stem cells. The invention includes pharmaceutical compositions and uses of either the multipotent stem cells or the
10 differentiated cells derived from such stem cells. The invention further provides methods of differentiating multipotent stem cells to neural and non-neural cell types. Additionally, business methods based on the multipotent stem cells or the differentiated cells are contemplated.

 There are a number of diseases of the central nervous system ("CNS")
15 which have a devastating effect on patients. These diseases are debilitating, often incurable, and include, for example, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Multiple Sclerosis.

 By way of example, Parkinson's disease is a progressive degenerative disorder of unknown cause. In healthy brain tissue, dopaminergic neurons extend
20 from the substantia nigra of the brain into the neighboring striatum. In Parkinson's disease, these dopaminergic neurons die.

 There are a number of methods to treat Parkinson's disease. One method is to treat humans having Parkinson's disease with L-DOPA. A second method is to transplant cells into the substantia nigra or striatum. Transplanted cells replace
25 endogenous cells that are lost as a consequence of disease progression. An animal model of Parkinson's disease is an MPTP-treated non-human primate. The MPTP-treated animals have been transplanted with dopamine-rich embryonic neurons with some success.

 To date, the cells used for neural transplant have been collected from the
30 developing brains of aborted fetuses. Aside from the ethical considerations, the method from a practical standpoint is unlikely to provide a sufficient amount of

neural tissue to meet the demands. Thus, another source of cells for transplantation is desirable.

In addition to conditions affecting the nervous system, multipotent stem cells, or cells differentiated from multipotent stem cells, represent a potential treatment for conditions involving cell damage or cell loss to nearly any tissue. For example, transplantation of multipotent stem cells, or cell differentiated from multipotent stem cells, may be used to replace damaged heart muscle following a heart attack, may be used to replace damaged cartilage following injury, may be used to replace pancreatic tissue damaged by diabetes or pancreatic cancer, or may be used to provide additional adipose tissue to abrogate the wasting associated with many diseases.

Stem cells are undifferentiated cells that exist in many tissues of embryos and adult organisms. In embryos, blastocyst stem cells are the source of cells which differentiate to form the specialized tissues and organs of the developing fetus. In adults, specialized stem cells in individual tissues are the source of new cells, replacing cells lost through cell death due to natural attrition, disease, or injury. Stem cells may be used as substrates for producing healthy tissue where a disease, disorder, or abnormal physical state has destroyed or damaged normal tissue.

Weiss et al., 1996 summarizes the five defining characteristics of stem cells as the ability to:

- Proliferate: Stem cells are capable of dividing to produce daughter cells.
- Exhibit self-maintenance or renewal over the lifetime of the organism: Stem cells are capable of reproducing by dividing symmetrically or asymmetrically to produce new stem cells. Symmetric division occurs when one stem cell divides into two daughter stem cells. Asymmetric division occurs when one stem cell forms one new stem cell and one progenitor cell. Symmetric division is a source of renewal of stem cells. This permits stem cells to maintain a consistent level of stem cells in an embryo or adult mammal.
- Generate large number of progeny: Stem cells may produce a large number of progeny through the transient amplification of a population of progenitor cells.

- Retain their multilineage potential over time: Stem cells are the ultimate source of differentiated tissue cells, so they retain their ability to produce multiple types of progenitor cells, which will in turn develop into specialized tissue cells.
- 5 • Generate new cells in response to injury or disease: This is essential in tissues which have a high turnover rate or which are more likely to be subject to injury or disease, such as the epithelium of blood cells.

Thus, the key features of stem cells are that they are multipotential cells which are capable of long-term self-renewal over the lifetime of a mammal.

10 MSCs may be used as a source of cells for transplantation. The stem cells may themselves be transplanted or, alternatively, they may be induced to produce differentiated cells (*e.g.*, neurons, oligodendrocytes, Schwann cells, or astrocytes) for transplantation. Transplanted stem cells may also be used to express therapeutic molecules, such as growth factors, cytokines, anti-apoptotic proteins, and
15 the like. Thus, stem cells are a potential source of cells for alternative treatments of diseases involving loss of cells or tissues.

The safest type of tissue graft (using stem cells or otherwise) is one that comes from self (an autologous tissue source). Autologous tissue sources are widely used in procedures such as bone transplants and skin transplants because a source of
20 healthy tissue is readily accessible for transplant to a damaged tissue site. In brain diseases, such as Parkinson's disease, healthy dopaminergic neuronal brain tissue may exist at other sites in the brain, but attempts to transplant these neurons may harm the site where the healthy neurons originate. Multipotent stem cells that can be differentiated into dopaminergic neurons may be available at other sites from which
25 they may be transplanted, but the CNS, particularly the brain, is physically difficult to access. Accordingly, the multipotent stem cells of the present invention, or cells differentiated from the multipotent stem cells of the present invention, represent a significantly improved treatment option for a variety of conditions affecting both neural and non-neural cell types.

30 In several tissues, stem cells have been purified and characterized. For example, neural stem cells have been purified from the mammalian forebrain (Reynolds and Weiss, *Science* 255:1707-1710, 1992) and these cells were shown to

be capable of differentiating into neurons, astrocytes, and oligodendrocytes. PCT publications WO 93/01275, WO 94/16718, WO 94/10292 and WO 94/09119 describe uses for these cells. It could be impractical or impossible, however, to first access brain or other CNS tissue for biopsy and then again for transplant in patients with weakened health. It would be very useful if there were accessible stem cells capable of differentiating into CNS cell types, such as dopaminergic neurons; such cells would be a source of cells for autologous transplants.

Thus, there is a clear need to develop methods for identifying from accessible tissues multipotent stem cells that can act as a source of cells that are transplantable to the CNS, PNS, or other tissues *in vivo* in order to replace damaged or diseased tissue. The present invention provides a readily accessible source of stem cells which can differentiate into both neural and non-neural cell types. The methods and compositions of the present invention offer previously unavailable treatments for a wide range of diseases and injuries which affect both neural and non-neural tissues.

Summary of the Invention

One aspect of the present invention relates to preparations of purified multipotent stem cells that are obtained from peripheral tissue of mammals, preferably from postnatal mammals such as juvenile and adult mammals. We have identified epithelial tissues, such as skin, as convenient sources of multipotent stem cells, and provide methods for the purification of epithelial-derived MSCs, thus simplifying the harvesting of cells for transplantation relative to previous methods. The MSCs possess desirable features in that they are multipotent and self-renewing. The cells can be repeatedly passaged and can be differentiated into numerous cell types of the body including derivatives of ectodermal and mesodermal tissue. The MSCs of this invention are positive for nestin protein, an immunological marker of stem cells and progenitor cells, as well as fibronectin protein when assayed by immunohistochemistry. Moreover, the MSCs of the present invention grow as non-adherent clusters when cultured by the methods herein disclosed, and one of skill in the art will readily recognize that such cells will grow as non-adherent clusters when

cultured on a variety of substratum including but not limited to uncoated plastic or plastic coated with a neutral substrate such as gelatin or agar. In certain embodiments, the MSCs of this invention are negative for the neural crest stem cell marker p75. In certain other embodiments, the MSCs of this invention are positive
5 for vimentin and/or cytokeratin. These characteristics distinguish the cells of the present invention from previously described stem cells, including mesenchymal stem cells, neurospheres, and neural crest stem cells.

In certain embodiments, the cells are capable of differentiating as dopaminergic neurons, and thus are a useful source of dopaminergic neurons for
10 homotypic grafts into Parkinson's Disease patients. The MSCs can also differentiate as numerous mesodermal derivatives including smooth muscle cells, adipocytes, cartilage, bone, skeletal muscle, and cardiac muscle, and are expected to be capable of producing other mesodermal derivatives including kidney and hematopoietic cells. Additionally, we show that the MSCs can express markers of endodermal
15 differentiation, and are expected to differentiate to cell types including pancreatic islet cells (e.g., alpha, beta, phi, delta cells), hepatocytes, and the like. The subject cells may also be used for autologous or heterologous transplants to treat, for example, other neurodegenerative diseases, disorders, or abnormal physical states. Further examples of conditions which can be treated by transplantation of the
20 multipotent stem cells of the invention include, but are not limited to, Huntington's disease, Alzheimer's disease, ALS, multiple sclerosis, spinal cord injuries, peripheral neuropathies, myocardial damage, diabetes, arthritis, peripheral vascular disease, cardiovascular disease, and the wasting associated with age and disease. Furthermore, transplantation of the multipotent stem cells of the invention can be
25 used to treat a range of injuries including, but not limited to, broken bones, torn muscles, torn ligaments, torn cartilage, and torn tendons.

Accordingly, in a first aspect, the invention features MSCs substantially purified from a peripheral tissue of a postnatal mammal. In preferred embodiments, the peripheral tissue is an epithelial tissue including skin or mucosal tissue. In a
30 second embodiment, the peripheral tissue is derived from the tongue. In still another embodiment, the tissue is derived from skin. The postnatal mammal may be either a juvenile or adult mammal.

In certain embodiments, the invention features a cell that is the progeny of a MSC substantially purified from a peripheral tissue of a postnatal mammal. The cell may be a mitotic cell or a differentiated cell (*e.g.*, a neuron, an astrocyte, an oligodendrocyte, a Schwann cell, or a non-neural cell). Preferred neurons include
5 neurons expressing one or more of the following neurotransmitters: dopamine, GABA, glycine, acetylcholine, glutamate, and serotonin. Preferred non-neural cells include cardiac muscle cells, pancreatic cells (*e.g.*, islet cells (alpha, beta, phi and delta cells), exocrine cells, endocrine cells, chondrocytes, osteocytes, skeletal muscle cells, smooth muscle cells, hepatocytes, hematopoietic cells, and adipocytes.
10 These non-neural cell types include both mesodermal and endodermal derivatives. In a preferred embodiment, the differentiated cells are substantially purified.

In a second aspect, the invention features a population of at least ten cells, wherein at least 30% of the cells are MSCs substantially purified from a peripheral tissue of a postnatal mammal or progeny of the MSCs.

15 Preferably, at least 50% of the cells are MSCs substantially purified from the peripheral tissue or progeny of the MSCs. More preferably, at least 75% of the cells are MSCs substantially purified from the peripheral tissue or progeny of the MSCs. Most preferably, at least 90%, 95%, or even 100% of the cells are MSCs substantially purified from the peripheral tissue or progeny of the MSCs. The MSCs
20 may be cultured for extended periods of time. Thus, the population of cells may have been in culture for at least thirty days, sixty days, ninety days, or longer (*e.g.*, one year or more). Preferably, the population is at least twenty cells, and may be more than fifty cells, a thousand cells, or even a million cells or more.

In a third aspect, the invention features preparations of at least ten cells,
25 and more preferably at least 10^4 , 10^5 , 10^6 or even 10^7 cells, having less than 25% lineage committed cells. Preferably, less than 20% of the cells are lineage committed cells. More preferably, less than 15% of the cells are lineage committed cells. Most preferably, less than 10%, 5%, or even 0% of the cells are lineage committed cells. In general, any cell feeder layer upon which the cells of the
30 invention are cultured would not be considered in such a calculation.

In a fourth aspect, the invention features a pharmaceutical composition including (i) a mitotic or differentiated cell that is the progeny of a MSC

substantially purified from a peripheral tissue of a postnatal mammal, and (ii) a pharmaceutically acceptable carrier, auxiliary or excipient.

5 In a fifth, related aspect, the invention features a pharmaceutical composition including (i) a MSC substantially purified from a peripheral tissue of a postnatal mammal, and (ii) a pharmaceutically acceptable carrier, auxiliary or excipient.

10 Preferably, the composition of the fourth or fifth aspect includes a population of cells, wherein at least 30%, 50%, 75%, 90%, 95%, or even 100% of the cells are MSCs substantially purified from the peripheral tissue or progeny of the MSCs. The composition may include one or more types of cells selected from a group consisting of MSCs, or neurons, oligodendrocytes, Schwann cells, astrocytes, adipocytes, smooth muscle cells, cardiomyocytes, chondrocytes, osteocytes, skeletal muscle cells, hepatocytes, hematopoietic cells, exocrine cells, endocrine cells and alpha, beta, phi and delta cells, which are progeny of MSCs.

15 In a sixth aspect, the invention features a method of producing a population of at least ten cells, wherein at least 30% of the cells are MSCs substantially purified from a peripheral tissue of a postnatal mammal or progeny of the MSCs: (a) providing the peripheral tissue from the mammal; (b) culturing the tissue under conditions in which MSCs proliferate and in which at least 25% of the cells that are not MSCs die; and (c) continuing culture step (b) until at least 30% of the cells are MSCs or progeny of the MSCs.

20 In a seventh aspect, the invention features another method of producing a population of at least ten cells, wherein at least 30% of the cells are MSCs substantially purified from skin tissue of a postnatal mammal or progeny of the MSCs, the method including: (a) providing the skin tissue from the mammal; (b) culturing the tissue under conditions in which MSCs proliferate and in which at least 25% of the cells that are not MSCs die; (c) separating the MSCs from cells that are not MSCs based on the tendency of MSCs to form non-adherent clusters; and (d) repeating steps (b) and (c) until at least 30% of the cells are MSCs or progeny of the MSCs.

30 Suitable culture conditions for step (b) of the sixth and seventh aspects are preferably as follows: (i) triturating or otherwise separating tissue into single

cells or cell clusters and placing into culture medium; (ii) culturing the cells in culture medium and under conditions (*e.g.*, DMEM: Ham's F-12 medium containing B-27 supplement, antibacterial and antifungal agents, 5-100 ng/ml bFGF, and 2-100 ng/ml EGF) that allows for the proliferation of MSCs but does not promote, to the same extent, proliferation of cells that are not MSCs; and (iii) culturing the separated tissue for three to ten days, during which time the MSCs proliferate in suspension and form non-adherent clusters but non-MSCs do not proliferate in suspension (these cells either attach to the plastic or they die). Preferably, at least 50% of the cells in suspension surviving after the period in culture are MSCs or progeny of the MSCs, more preferably, at least 75% of the cells are MSCs or progeny of the MSCs, and, most preferably, at least 90% or even 95% of the surviving cells are MSCs or progeny of the MSCs. In preferred embodiments, tissue is separated mechanically.

In an eighth aspect, the invention features a method of treating a patient having a disease associated with cell loss. In one embodiment, the method includes the step of transplanting the multipotent stem cells of the invention into the region of the patient in which there is cell loss. Preferably, prior to the transplanting step, the method includes the steps of providing a culture of peripheral tissue and isolating a multipotent stem cell from the peripheral tissue. The tissue may be derived from the same patient (autologous) or from either a genetically related or unrelated individual. After transplantation, the method may further include the step of differentiating (or allowing the differentiation of) the MSCs into a desired cell type to replace the cells that were lost. Preferably, the region is a region of the CNS or PNS, but can also be cardiac tissue, pancreatic tissue, or any other tissue in which cell transplantation therapy is possible. In a second embodiment, the method includes the step of delivering the stem cells to the site of cell damage via the bloodstream, wherein the stem cells home to the site of cell damage. In a third embodiment, the method for treating a patient includes the transplantation of the differentiated cells which are the progeny of the stem cells of this invention.

In a further embodiment, the invention contemplates that stem cells, or cells differentiated from the multipotent stem cells of the invention, are modified prior to transplantation to express a therapeutic protein. Such a therapeutic protein is preferably one that will influence the proliferation, differentiation, migration,

and/or survival of the transplanted cell and thus promote the treatment of the disease or injury.

In still a further embodiment, the invention contemplates, prior to transplantation, biasing or promoting the differentiation of a multipotent stem cell toward a particular developmental pathway. For example, prior to transplantation, a population of multipotent stem cells could be treated (e.g., cultured under specific conditions) to promote their eventual differentiation along a neuronal fate. Such biased cells could then be transplanted to treat a neurodegenerative condition.

In any of the foregoing examples of this aspect of the present invention, it is contemplated that the transplantation of multipotent stem cells, or cells differentiated from multipotent stem cells, may further influence proliferation, differentiation or survival of the endogenous tissue. Without wishing to be bound by any particular theory, transplanted cells may secrete factors which recruit endogenous cells and help to potentiate the therapeutic efficacy of the transplantation.

In any of the foregoing examples of this aspect of the present invention, it is contemplated that, prior to transplantation of multipotent stem cells or differentiated progeny, the cells will be sorted. Cells may be sorted based on, for example, expression of one or more genes or proteins. The sorting of cells prior to transplantation allows for the selection of and transplantation of only cells meeting particular criteria. For example, if cells are modified prior to transplantation to express a given therapeutic protein, it may be desirable to sort transfected cells so that only cells which are expressing that therapeutic protein are transplanted.

In a ninth aspect, the invention features a kit including MSCs substantially purified from peripheral tissue of a postnatal mammal, or a mitotic or differentiated cell that is the progeny of the MSC, preferably wherein the peripheral tissue from which the MSC is purified includes a sensory receptor. Preferably, the kit includes a population of cells, wherein at least 30%, 50%, 75%, 90%, or even 95% of the cells are MSCs substantially purified from the peripheral tissue or progeny of the MSCs.

In a tenth aspect, the invention features a kit for purifying MSCs from peripheral tissue. The kit includes media or media components that allow for the

substantial purification of MSCs of the present invention. The kit may also include media or media components that allow for the differentiation of the MSCs into the desired cell type(s). Preferably, the kit also includes instructions for its use. In one embodiment, the media includes one or more therapeutic proteins, pharmaceutical
5 agents, and/or small molecules that influence the proliferation, differentiation, and/or survival of the MSCs.

In one preferred embodiment of each of the foregoing aspects of the invention, the peripheral tissue is skin tissue. In another preferred embodiment, the peripheral tissue is olfactory epithelium, tongue tissue, hair follicles, sweat glands,
10 or sebaceous glands. In another preferred embodiment, the multipotent stem cells are derived from a peripheral tissue which does not include olfactory epithelium. Cultures of stem cells derived from olfactory epithelium can be identified based on the expression of markers specific for the olfactory epithelium. For example, cultures of stem cells derived from olfactory epithelium may contain a low
15 percentage of differentiated olfactory epithelial tissue. Such low percentage of differentiated tissue is preferably less than 10% of the substantially purified cultures of stem cells, more preferably less than 5% of the substantially purified culture, and expresses one or more specific markers of differentiated olfactory epithelium. In a preferred embodiment, such cells express olfactory marker protein (OMP), when
20 assayed by immunocytochemistry. In another preferred embodiment of each of the foregoing aspects of the invention, the stem cells are negative for p75. Throughout the application, one of skill in the art will recognize that when the cells of the present invention are characterized as negative for the expression of a specific marker, it is understood to mean substantially negative. By substantially negative
25 (also referred to herein as essentially negative) is meant that less than 5%, 4%, 3%, 2%, or even 1% of the cells in a purified preparation of cells are positive for a given marker. The term substantially negative takes into account that even a purified population of cells may contain some contaminants from surrounding tissue, or may contain some lineage committed cells.

30 The peripheral tissue can be from a newborn mammal, a juvenile mammal, or an adult mammal. Preferred mammals include, for example, humans, non-human primates, mice, pigs, and rats. The MSCs can be derived from

peripheral tissue of any individual, including one suffering from a disease or from an individual immunologically compatible to an individual suffering from a disease. In a preferred embodiment, the cells, or progeny of the cells, are transplanted into the CNS or PNS of an individual having a neurodegenerative disease and the individual is the same individual from whom the MSCs were purified. Following transplantation, the cells can differentiate into cells that are lacking or non-functional in the disease. In another preferred embodiment, the cells, or progeny of the cells, are transplanted to the heart of a patient whose myocardium was damaged following myocardial infarction or ischemia. Following transplantation, the cells can differentiate to replace the damaged myocardial tissue. In still another preferred embodiment, the cells, or progeny of the cells are transplanted to the joints of a patient whose cartilage has been ravaged by arthritis. Following transplantation, the cells can differentiate to replace the damaged cartilage tissue. In still another embodiment, the cells, or progeny thereof, are transplanted as part of a treatment to repair a torn ligament or tendon. The present invention contemplates the transplantation of stem cells, or the progeny thereof, to treat a wide range of diseases, injuries, and conditions which affect cell types derived from both ectoderm and mesoderm, and the foregoing examples serve merely to illustrate the wide range of conditions amenable to such treatment.

Preferably, the MSCs are positive for nestin and fibronectin protein. In one embodiment, the MSCs are negative (substantially negative) for p75. In another embodiment, the MSCs are positive for vimentin and/or cytokeratin. The MSCs of the present invention can, under appropriate conditions, differentiate into neurons, astrocytes, Schwann cells, oligodendrocytes, and/or non-neural cells (e.g., cardiac muscle cells, skeletal muscle cells, pancreatic cells, smooth muscle cells, adipocytes, hepatocytes, cartilage, bone, etc.). In a preferred embodiment, the differentiated neurons are dopaminergic neurons. In another preferred embodiment, the differentiated cells are Schwann cells. In still another preferred embodiment, the differentiated non-neural cells are selected from smooth muscle cells, adipocytes, cartilage, bone, skeletal muscle, or cardiac muscle.

We show that the MSCs of the invention have tremendous capacity to differentiate into a range of neural and non-neural cell types. The non-neural cell

types include both mesodermal and endodermal derivatives. Accordingly, the present invention provides methods for differentiating MSCs to neural and/or non-neural cell types. Furthermore, the capacity of the multipotent stem cells of the present invention to differentiate to neural and non-neural cell types can be

5 influenced by modulating the culture conditions to influence the proliferation, differentiation, and survival of the MSCs. In one embodiment, modulating the culture conditions includes increasing or decreasing the serum concentration. In another embodiment, modulating the culture conditions includes increasing or decreasing the plating density. In still another embodiment, modulating the culture

10 conditions includes the addition of one or more pharmacological agents to the culture medium. In another embodiment, modulating the culture conditions includes the addition of one or more therapeutic proteins (i.e., growth factors, cytokines, anti-apoptotic proteins) to the culture medium. In still another embodiment, modulating the culture conditions includes the addition of one or more small molecules that

15 agonize or antagonize the function of a protein involved in cell proliferation, differentiation, or survival. In each of the foregoing embodiments, pharmacological agents, therapeutic proteins, and small molecules can be administered individually or in any combination, and combinations of any of the pharmaceutical agents, therapeutic proteins, and small molecules can be co-administered or administered at

20 different times. As a result of modulating the culture conditions to influence the proliferation, differentiation or survival of the stem cells of the invention, the present invention provides cultures which are enriched for particular cell types differentiated from the multipotent stem cells of the invention.

MSCs can be stably or transiently transfected with a heterologous gene

25 (e.g., one encoding a therapeutic protein, such as a protein which enhances cell divisions or prevents apoptosis of the transformed cell or other cells in the patient, or a cell fate-determining protein). In one embodiment, the heterologous gene modulates one or more of cell proliferation, differentiation, or survival. In preferred embodiments, transfection of the heterologous gene is adenoviral mediated. In

30 another preferred embodiment, transfection occurs using standard protocols for transfection in cell culture including lipofectamine mediated transfection or electroporation.

In an eleventh aspect, the invention features preparations of stem cells and their differentiated progeny preserved for subsequent retrieval. In one preferred embodiment, the preserved cells are formulated in a pharmaceutically acceptable carrier. In another embodiment, the stem cells or differentiated progeny are
5 preserved using cryogenic methods.

In a twelfth aspect, the invention features a method for conducting a regenerative medicine business. In one embodiment, the method comprises accepting and cataloging tissue samples from a client, culturing the cells from said sample to expand the multipotent stem cells, preserving such cells and storing them
10 for later retrieval. In a second embodiment, the method comprises accepting and cataloging tissue samples from a client, culturing the cells from said sample to expand the multipotent stem cells, and differentiating the stem cell. Both of these embodiments also contemplate a billing system for billing the client or an insurance provider.

In a thirteenth aspect, the invention features a method for conducting a stem cell business comprising identifying agents which influence the proliferation, differentiation, or survival of the multipotent stem cells of the invention. Such agents include small molecules and extracellular proteins. In a preferred
15 embodiment, the identified agents could be profiled and assessed for safety and efficacy in animals. In another preferred embodiment, the invention contemplates methods for influencing the proliferation, differentiation, or survival of the multipotent stem cells of the invention by contacting the cells with an agent or agents identified by the foregoing method. In another preferred embodiment, the
20 identified agents are formulated as a pharmaceutical preparation. This pharmaceutical preparation can be manufactured, marketed, and distributed for sale.

In a fourteenth aspect, the invention includes a method for conducting a drug discovery business comprising identifying factors which influence the proliferation, differentiation, or survival of the multipotent stem cells of the invention, and licensing the rights for further development.

In the foregoing aspects of the invention, it is appreciated that the MSCs of
30 the invention can proliferate in culture, and differentiate to derivatives of all three germ layers. Therefore, the MSCs provide novel compositions of adult stem cells

which have therapeutic applications in treating conditions which affect a wide range of cell types. Recognizing the ability of these cells to differentiate to derivatives of all three germ layers, in a fifteen aspect, the invention includes a cellular composition of adult stem cells which (i) will proliferate in an in vitro culture, (ii) maintains the potential to differentiate to derivatives of endoderm, mesoderm, and ectoderm tissues throughout the culture, and (iii) is inhibited from differentiation when cultured under proliferative conditions.

Furthermore, in a sixteenth aspect, the invention includes a cellular composition of adult stem cells which (i) will proliferate in an in vitro culture for over one year, (ii) maintains a karyotype in which the chromosomes are euploid and not altered through prolonged culture, (iii) maintains the potential to differentiate to derivatives of endoderm, mesoderm, and ectoderm tissues throughout the culture, and (iv) is inhibited from differentiation when cultured under proliferative conditions.

For convenience, certain terms employed in the specification, examples, and appended claims are collected here.

By “multipotential stem cell” is meant a cell that (i) has the potential of differentiating into at least two cell types selected from a neuron, an astrocyte, and an oligodendrocyte, and (ii) exhibits self-renewal, meaning that at a cell division, at least one of the two daughter cells will also be a stem cell. The non-stem cell progeny of a single MSC are capable of differentiating into neurons, astrocytes, Schwann cells, and oligodendrocytes. Hence, the stem cell is “multipotent” because its progeny have multiple differentiative pathways. The MSC also has the potential to differentiate as another non-neuronal cell type (*e.g.*, a skin cell, a hematopoietic cell, a smooth muscle cell, a cardiac muscle cell, a skeletal muscle cell, a bone cell, a cartilage cell, a pancreatic cell or an adipocyte).

By a “population of cells” is meant a collection of at least ten cells. Preferably, the population consists of at least twenty cells, more preferably at least one hundred cells, and most preferably at least one thousand or even one million cells. Because the MSCs of the present invention exhibit a capacity for self-renewal, they can be expanded in culture to produce populations of even billions of cells.

By “therapeutic protein” is meant a protein that improves or maintains the health of the cell expressing the protein or of a cell that is in proximity to the expressing cell. The term therapeutic protein shall encompass any protein that influences the proliferation, differentiation, and/or survival of the cells of the invention, without regard to the mechanism by which the therapeutic protein has this effect. Examples of therapeutic proteins include, without limitation, growth factors (NGF, BDNF, NT-3, NT-4/5, HGF, TGF- β family members, PDGF, GDNF, FGF, EGF family members, IGF, insulin, BMPs (-2, 4, 5, 6, 7, 8), Wnts, hedgehogs (Sonic, Desert, Indian), and heregulins) cytokines (LIF, CNTF, TNF μ interleukins, and gamma-interferon), and anti-apoptotic proteins (IAP proteins, Bcl-2 proteins, Bcl-X_L, Trk receptors, Akt, PI3 kinase, Gab, Mek, E1B55K, Raf, Ras, PKC, PLC, FRS2, rAPs/SH2B, and Np73). Additionally, therapeutic proteins include receptors for and the intracellular components of signal transduction pathways. These signal transduction pathway are well known in the art (hedgehog pathway, Wnt pathway, BMP pathway, Notch pathway, FGF, etc), and one of skill will recognize that expression and/or treatment with components (ligands, receptors, or intracellular components) of a signal transduction pathway can modulate signaling via that pathway with subsequent effects on cell proliferation, differentiation, and/or survival.

By “small molecule” is meant a compound having a molecular weight less than about 2500 amu, preferably less than about 2000 amu, even more preferably less than about 1500 amu, still more preferably less than about 1000 amu, or most preferably less than about 750 amu. “Small organic molecule” are those small molecules which contain carbon.

By “plating conditions” is meant to include any and all parameters that influence the proliferation, differentiation, and/or survival of cells. Plating conditions include, but are not limited to, changes in serum concentration, changes in plating density, the use of various feeder layers and co-cultures, the addition of therapeutic proteins to the culture media, the addition of small molecules to the culture media, the addition of pharmacological agents to the culture media, and the addition of metals to the culture media. Any of these parameters may be altered individually or in combination, and combinations of these parameters can be

manipulated at the same time or at different times. Additionally, it is understood, that the MSCs can be sorted prior to plating, such that a sub-population of MSCs are subjected to the differentiation conditions. Sorting of the MSCs may be based on the expression (or lack of expression) of a gene or protein. Furthermore, sorting of the MSCs may be based on cellular characteristics including cell adhesion, or morphology.

By “peripheral tissue” is meant a tissue that is not derived from neuroectoderm, for example peripheral tissue containing sensory receptors, and specifically includes olfactory epithelium, tongue, skin (including dermis and/or epidermis), and mucosal layers of the body (e.g., mouth, reproductive system).

By “epithelia” and “epithelium” is meant the cellular covering of internal and external body surfaces (cutaneous, mucous and serous), including the glands and other structures derived therefrom, e.g., corneal, esophageal, epidermal, and hair follicle epithelial cells. Other exemplary epithelial tissue includes: olfactory epithelium, which is the pseudostratified epithelium lining the olfactory region of the nasal cavity, and containing the receptors for the sense of smell; glandular epithelium, which refers to epithelium composed of secreting cells; squamous epithelium, which refers to epithelium composed of flattened plate-like cells. The term epithelium can also refer to transitional epithelium, that which is characteristically found lining hollow organs that are subject to great mechanical change due to contraction and distention, e.g. tissue which represents a transition between stratified squamous and columnar epithelium. The term “epithelialization” refers to healing by the growth of epithelial tissue over a denuded surface.

By “skin” is meant the outer protective covering of the body, consisting of the corium and the epidermis, and is understood to include sweat and sebaceous glands, as well as hair follicle structures. Throughout the present application, the adjective “cutaneous” may be used, and should be understood to refer generally to attributes of the skin, as appropriate to the context in which they are used.

By “epidermis” is meant the outermost and nonvascular layer of the skin, derived from the embryonic ectoderm, varying in thickness from 0.07-1.4 mm. On the palmar and plantar surfaces it comprises, from within outward, five layers: basal layer composed of columnar cells arranged perpendicularly; prickle-cell or spinous

layer composed of flattened polyhedral cells with short processes or spines; granular layer composed of flattened granular cells; clear layer composed of several layers of clear, transparent cells in which the nuclei are indistinct or absent; and horny layer composed of flattened, conified non-nucleated cells. In the epidermis of the general
5 body surface, the clear layer is usually absent. An "epidermoid" is a cell or tissue resembling the epidermis, but may also be used to refer to any tumor occurring in a noncutaneous site and formed by inclusion of epidermal elements.

By "ectoderm" is meant the outermost of the three primitive germ layers of the embryo; from which are derived the epidermis and epidermal tissues such as
10 the nails, hair and glands of the skin, the nervous system, external sense organs and mucous membrane of the mouth and anus.

By "mesoderm" is meant the middle of the three primitive germ layers of the embryo; from which are derived the heart, kidney, skeletal muscle, bone, cartilage, blood, endothelial lining of blood vessels, adipose tissue, and the
15 urogenital system.

By "endoderm" is meant the innermost of the three primitive germ layers of the embryo; from which are derived the lungs, trachea, pharynx, thyroid, pharyngeal pouch derivatives, and the organs of the gut including the stomach, small intestines, large intestines, pancreas, liver, gall bladder, appendix, esophagus,
20 rectum, anus, and urinary bladder.

By "differentiation" is meant the formation of cells expressing markers known to be associated with cells that are more specialized and closer to becoming terminally differentiated cells incapable of further division or differentiation.

By "lineage committed cell" is meant a progenitor cell that is no longer
25 pluripotent but has been induced to differentiate into a specific cell type, e.g., a dopaminergic neuron.

By "proliferation" is meant an increase in cell number.

By "non-adherent clusters" is meant that the cells of the invention are able to adhere to each other and form clusters which increase in size as the cells
30 proliferate, but these cells do not adhere to the substratum and grow in suspension,

wherein the substratum is uncoated tissue culture plastic or a culture vessel coated with a neutral coating such as agar or gelatin.

By “dissociating a sample” is meant to separate tissue into either single cells, smaller cell clusters, or smaller pieces of tissue.

5 By “postnatal” is meant an animal that has been born at term.

By “a disease characterized by failure of a cell type” is meant one in which the disease phenotype is the result of loss of cells of that cell type or the loss of function of cells of that cell type.

10 By “autologous transplant” is meant that the transplanted material (e.g., MSCs or the progeny or differentiated cells thereof) is derived from and transplanted to the same individual.

By “nucleic acid” is meant polynucleotides such as deoxyribonucleic acid (DNA), and, where appropriate, ribonucleic acid (RNA). The term should also be understood to include, as equivalents, analogs of either RNA or DNA made from
15 nucleotide analogs, and, as applicable to the embodiment being described, single (sense or antisense) and double-stranded polynucleotides.

By “gene” is meant a nucleic acid comprising an open reading frame encoding a polypeptide, including both exon and (optionally) intron sequences.

20 By “transfection” is meant the introduction of a nucleic acid, e.g., an expression vector, into a recipient cell by nucleic acid-mediated gene transfer.

As used herein, the term “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of preferred vector is an episome, i.e., a nucleic acid capable of extra-chromosomal replication. Preferred vectors are those capable of autonomous replication
25 and/expression of nucleic acids to which they are linked. Vectors capable of directing the expression of genes to which they are operatively linked are referred to herein as “expression vectors”. In general, expression vectors of utility in recombinant DNA techniques are often in the form of “plasmids” which refer generally to circular double stranded DNA loops which, in their vector form are not
30 bound to the chromosome. In the present specification, “plasmid” and “vector” are used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors

which serve equivalent functions and which become known in the art subsequently hereto.

“Transcriptional regulatory sequence” is a generic term used throughout the specification to refer to DNA sequences, such as initiation signals, enhancers, and promoters, which induce or control transcription of protein coding sequences with which they are operably linked. It will also be understood that the recombinant gene can be under the control of transcriptional regulatory sequences which are the same or which are different from those sequences which control transcription of the naturally-occurring gene.

By “tissue-specific promoter” is meant a DNA sequence that serves as a promoter, i.e., regulates expression of a selected DNA sequence operably linked to the promoter, and which effects expression of the selected DNA sequence in specific cells of a tissue, such as cells of neuronal or hematopoietic origin. The term also covers so-called “leaky” promoters, which regulate expression of a selected DNA primarily in one tissue, but can cause at least low level expression in other tissues as well.

Other features and advantages of the present invention will become apparent from the following detailed description and the claims. It will be understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by way of example only, and various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

Brief Description of the Drawings

Figs. 1A-1G are photographs showing that mouse skin-derived MSCs are nestin-positive and are capable of differentiating into neurons, glia, and smooth muscle cells.

Fig. 2 is a series of photographs showing that neonate and adult mouse skin-derived MSCs express both nestin (middle row) and fibronectin protein (bottom row).

Fig. 3A is a series of photographs showing western blot analysis for
5 nestin, neurofilament M (NF-M) and GFAP in cells differentiated from neonate and adult mouse skin-derived MSCs.

Fig. 3B is a series of photographs showing that human skin-derived MSCs express nestin.

Fig. 3C is a series of photographs showing that a subset of
10 morphologically complex cells expressed nestin and β tubulin, a profile typical of newly-born neurons.

Fig. 3D is a series of photographs showing that GFP positive cells are also positive for neuron-specific enolase.

Fig. 4A is a photograph showing the expression of A2B5, a marker for
15 oligodendrocyte precursors, on undifferentiated mouse skin-derived MSCs.

Fig. 4B is a photograph showing the expression of the oligodendrocyte marker galactocerebroside (GalC) on cells differentiated from mouse skin-derived MSCs.

Fig. 5 is a series of photographs showing that the fate of mouse skin-
20 derived MSCs can be manipulated by controlling plating conditions.

Fig. 6 is a series of photographs showing that neonate and adult mouse skin-derived MSCs can differentiate as adipocytes.

Figs. 7A and 7B are photographs showing that nestin-positive, fibronectin-positive MSCs can be derived from mouse dermis.

25 Figs. 8A and 8B are photographs showing that individual MSCs are multipotent. Clones derived from single cells contained NF-M-positive cells (arrowheads) and CNPase-positive cells (arrows). Arrowheads indicate cells that only express GFAP, while arrows indicate cells expressing both GFAP and CNPase.

Figs. 9A and 9B are photographs of western blot analysis of cells
30 differentiated from mouse skin-derived MSCs (Fig. 9A) or of MSCs themselves (Fig. 9B).

Fig. 10 is a series of photographs showing the effect of various pharmacological agents on mouse skin-derived MSCs.

Figs. 11A-11E are photographs of immunoprocessed sections of rat brains into which mouse skin-derived MSCs were transplanted.

5 Fig. 12 shows that nestin+, fibronectin+ skin-derived MSCs isolated from adult human scalp differentiate into cells that express a variety of neural and non-neural markers, as measured by immunocytochemistry with antibodies to β III-tubulin (A), CNPase (B), and smooth muscle actin (C), and GFAP (D).

10 Fig. 13 are photographs of skin-derived stem cells plated in 15 % FBS in the presence of skeletogenic supplements and cultured for two weeks. The cells are stained with Alcian Blue which reveals nodules of chondrocyte-associated acidic proteoglycans.

15 Fig. 14 are photographs of skin-derived stem cells plated in 15 % FBS in the presence of skeletogenic supplements and cultured for three weeks. The cells are stained with Alizarin Red which identified osteoblast-associated calcium accumulations.

20 Fig. 15 are photographs of skin-derived stem cells plated in 15 % FBS in the presence of skeletogenic supplements, cultured for three weeks, and co-stained with both Alcian Blue and Alizarin Red. Co-staining reveals that the calcium deposits occur within a layer of chondrocytic proteoglycan accumulation.

Fig. 16 are photographs of skin-derived stem cells plated in 15 % FBS in the presence of skeletogenic supplements and cultured for 4-5 weeks, and demonstrate the formation of optically dense deposits indicative of bone formation.

25 Fig. 17 shows that co-culture of GFP labeled skin-derived stem cells with cardiac myocytes induces expression of fetal cardiac actin. The expression of fetal cardiac actin co-localizes with GFP indicating that the differentiated cell is derived from the skin-derived stem cell.

30 Fig. 18 shows that co-culture of GFP labeled skin-derived stem cells with C2C12 cells induces expression of desmin. The expression of desmin co-localizes with GFP, and the morphology of this desmin expressing cell is indicative of a skeletal muscle cell.

Fig. 19 shows RT-PCR analysis of skin-derived MSCs grown in spheres (S), plated in proliferation media for three days (3d), or plated in proliferation media for three days followed by two days in 5 % serum (3d+2). The skin-derived MSCs express nestin, GATA-4, and Myf6. Positive controls (+ve) are: E10 brain (for nestin), embryoid bodies (for GATA-4), and muscle (for Myf6).

Fig. 20 shows that skin-derived MSCs express endodermal markers under certain differentiation conditions. Skin-derived MSCs were cultured under standard proliferation conditions in the presence or absence of B-27 supplement. Differentiation was induced by plating cells in the presence of nicotinamide, and the resulting differentiated cells were analyzed by quantitative RT-PCR. The graph demonstrates that skin-derived MSCs differentiated in the presence of nicotinamide express several markers of endodermal differentiation including GATA-4, HNF3 α , Isl1, AFP, HNF3 β , Ngn3, Pdx-1, and Insulin. Although cells proliferated in either the presence or the absence of B27 supplement can be induced to express endodermal markers, cells proliferated in B27 appear to express such markers to a higher degree.

Fig. 21 shows that agents, including therapeutic proteins and small molecules, influence the proliferation, differentiation, and/or survival of skin-derived stem cells. Cells were dissociated and plated in the presence of either 5 % FBS, 5 % FBS + retinoic acid (RA), or 5 % FBS + BMP7. Cells were analyzed immunocytochemically for expression of neurofilament M (NFM). Note the bottom panels shows a 40X magnification of the cells.

Fig. 22 shows that the skin-derived stem cells of the invention are a cell population distinct from mesenchymal stem cells. Mesenchymal stem cells and skin-derived stem cells were cultured under identical conditions, and immunocytochemical analysis was performed using antibodies to nestin and fibronectin. The top panels are photographs of mesenchymal stem cells, and the bottom panels are photographs of the skin-derived stem cells. Note not only the differences in protein expression, but also the differences in morphology between the two cell types.

Fig. 23 shows that skin-derived stem cells isolated from human foreskin proliferate as non-adherent clusters in culture. The top panels show that skin-

derived stem cells specifically isolated from the dermal layer of human foreskin proliferate as non-adherent clusters. In contrast to human central nervous system derived stem cells, the survival and proliferation of human skin-derived stem cells is not dependent on LIF. The bottom panels show that skin-derived stem cells isolated
5 from foreskin express nestin and fibronectin.

Fig. 24 shows that skin-derived stem cells isolated from human foreskin differentiate to form highly morphologically complex neurons as assayed by expression of bIII-tubulin and neurofilament-M (NF-M).

Fig. 25 shows that skin-derived stem cells isolated from human foreskin
10 differentiate to form glial cells as assayed by expression of GFAP and CNP.

Fig. 26 shows that skin-derived stem cells isolated from human foreskin differentiate to form additional neuronal cells types as assayed by expression of S100 and peripherin. S100 is a marker of bipolar cells and peripherin is a marker of peripheral neurons.

Fig. 27 shows that skin-derived stem cells isolated from human foreskin
15 differentiate to form non-neural cell types as assayed by expression of smooth muscle actin.

Fig. 28 shows that proliferating cultures of the multipotent stem cells of the present invention express both nestin and fibronectin protein. In contrast,
20 proliferating cultures of Neurospheres express nestin protein but do not express fibronectin protein.

Fig. 29 shows RT-PCR analysis of two transcription factors which are expressed in proliferating cultures of skin-derived multipotent stem cells but not in proliferating cultures of Neurospheres. Dermo-1 and SHOX2 are robustly
25 expressed in proliferating cultures of skin-derived stem cells, but are not expressed in proliferating cultures of Neurospheres.

Fig. 30 shows a schematic representation of the method used to bias multipotent stem cells to a neural fate. The method involves a proliferation phase, a pre-differentiation phase, and a differentiation phase. During the proliferation
30 phase, cells are cultured as non-adherent clusters under standard proliferation conditions. During the pre-differentiation phase, cells are plated on an adherent substrate (e.g., laminin, poly-D-lysine, etc), but maintained in the proliferation

media (+EGF, +FGF/no serum). During the differentiation phase, mitogens are withdrawn. Differentiation can be further influenced by the addition of factors to the media (e.g., therapeutic factors, serum, modulating plating conditions).

Although the differentiation phase is shown schematically to be one final continuous phase, we note that the differentiation phase can comprise several sub-phases where the cells are exposed to various differentiation conditions over the differentiation phase.

Fig. 31 shows that LIF increases the differentiation of cells to a neuronal fate. Proliferating cultures of skin derived stem cells were pre-differentiated for 3 days, and then cultured under differentiation conditions for 7 days in the presence or absence of LIF. The graph summarizes these results which demonstrate that cells differentiated in the presence of serum-free media and LIF show an increased expression of neuronal markers in comparison to cells differentiated in serum-free media alone.

Fig. 32 shows that LIF increases the differentiation of cells to a neuronal fate. Proliferating cultures of skin derived stem cells were pre-differentiated for 3 days, and then cultured under differentiation conditions for 7 days in the presence of 10% serum and LIF. The photo on the right (a high magnification view of the picture on the left) demonstrates that LIF (in the presence or absence of serum) increases neuronal differentiation of the stem cells of the present invention.

Fig. 33 shows that Sonic hedgehog promotes the differentiation of skin derived stem cells. Proliferating cultures of skin derived stem cells were pre-differentiated for 3 days in the presence or absence of Sonic hedgehog, and then cultured under differentiation conditions in 1% serum in the presence or absence of Sonic hedgehog. Fig. 33 demonstrates that treatment of the cells with Sonic hedgehog, during either the pre-differentiation or differentiation phase, promotes neuronal differentiation of the cells. We note the presence of TH⁺ neurons in these cultures.

Fig. 34 shows the various neural cell types which were observed when skin derived stem cells are pre-differentiated, and then cultured under differentiation conditions. Cells were cultured under pre-differentiation conditions for 3 days, and cultured under differentiation condition for 7 days in the presence of 10% serum.

Examples of markers observed in these experiments include: Dopamine- β -hydroxylase (D β H), peripherin, tyrosine hydroxylase (TH) and nestin. D β H is a marker of noradrenergic and adrenergic neurons, peripherin is a marker of peripheral neurons, and TH is a marker of dopaminergic neurons.

5 Fig. 35 shows the expression of MAP2, a marker of CNS and autonomic neurons, in cells differentiated for 10 days in 1% serum plus 50 mM KCl.

 Fig. 36 shows the differentiation of Schwann cells from skin derived multipotent stem cells. Proliferating cultures of skin derived stem cells were predifferentiated for 3 days, and then subjected to differentiation conditions for a
10 total of 8 days. During the first 5 days of the differentiation phase, the cell differentiation media was supplemented with 10% serum, and this media was additionally supplemented with forskolin during the final 3 days of the differentiation phase. Differentiated cells express Schwann cell markers including S100, MBP, and PMP22.

15 Fig. 37 shows that forskolin increases the differentiation of skin derived stem cells to Schwann cells. Proliferating cultures of skin derived stem cells were pre-differentiated for 3 days in 1% serum, and then cultured under differentiation conditions for 10 days in the presence or absence of forskolin. Treatment with forskolin increases the Schwann cell differentiation as assessed by both the
20 expression of Schwann cell markers and by morphology. Cells differentiated in the presence of forskolin are shown in the right panel, and cells differentiated in the absence of forskolin are shown in the left panel.

 Fig. 38 shows that heregulin β promotes Schwann cell differentiation. Proliferating cultures of skin derived stem cells were pre-differentiated for 3 days in
25 1% serum, and then cultured under differentiation conditions for 10 days in media supplemented with forskolin in the presence or absence of heregulin β . Comparison of the right panel (+heregulin β) with the left panel (-heregulin β) demonstrates that heregulin β promotes differentiation of Schwann cells.

 Fig. 39 shows that plating density influences Schwann cell differentiation
30 of skin derived multipotent stem cells. Proliferating cultures of skin derived stem cells were pre-differentiated for 3 days in the presence of 1% serum, and subjected to differentiation conditions for 10 days in the presence or absence of forskolin. To

assess the role of plating density on cell differentiation, serial dilutions of proliferating cells were subjected to the above conditions. The left panel shows cells plated at high density and differentiated in the presence of forskolin, while the right panel shows cells plated at low density and differentiated in the presence of
5 forskolin.

Fig. 40 shows a chart summarizing the effects of modulating various conditions on Schwann cell differentiation.

Fig. 41 summarizes the culture system. The hippocampus is dissected from P7-P9 rats pups, and sliced at 400 μ m using a tissue chopper. These slices are
10 placed in wells which float on a semiporous membrane. The slices are maintained at 37 °C/5% CO₂, and media is applied via a compartment beneath the slices. Approximately 5-7 days after dissection, the slices are ready for further experimentation.

Fig. 42 summarizes cell counting experiments. Proliferating cultures of
15 skin derived stem cells and olfactory epithelium derived stem cells were analyzed by immunocytochemistry for the expression of p75 protein, and the number of p75 positive cells were counted. The middle column summarizes the results of these cell counting experiments for skin derived stem cells which indicate that skin derived stem cells are essentially negative for the expression of p75 (less than 3% of the
20 cells are p75 positive). In contrast, the right hand column summarizes the results of cell counting experiments for olfactory epithelium derived stem cells which indicate that such cells express p75 protein (greater than 32% of the cells are p75 positive).

Best Mode for Carrying Out the Invention

Detailed Description of the Invention

We have substantially purified multipotent stem cells (MSCs) from peripheral tissues of mammals, including skin, olfactory epithelium, and tongue. These cells proliferate in culture, so that large numbers of stem cells can be generated. These cells can be induced to differentiate, for example, into neurons,
30 astrocytes, and/or oligodendrocytes by altering the culture conditions. They can also be induced to differentiate into non-neural cells such as smooth muscle cells, cartilage, bone, skeletal muscle, cardiac muscle, and adipocytes. The substantially

purified neural stem cells are thus useful for generating cells for use, for example, in autologous transplants for the treatment of degenerative disorders or trauma (*e.g.*, spinal cord injury). In one example, MSCs may be differentiated into dopaminergic neurons and implanted in the substantia nigra or striatum of a Parkinson's disease patient. In a second example, the cells may be used to generate oligodendrocytes for use in autologous transplants for the treatment of multiple sclerosis. In a third example, the MSCs may be used to generate Schwann cells for treatment of spinal cord injury, cardiac cells for the treatment of heart disease, or pancreatic islet cells for the treatment of diabetes. In a fourth example, MSCs may be used to generate adipocytes for the treatment of anorexia or wasting associated with many diseases including AIDS, cancer, and cancer treatments. In a fifth example, MSCs may be used to generate smooth muscle cells to be used in vascular grafts. In a sixth example, MSCs may be used to generate cartilage to be used to treat cartilage injuries and degenerative conditions of cartilage. In still another example, MSCs may be used to replace cells damaged or lost to bacterial or viral infection, or those lost to traumatic injuries such as burns, fractures, and lacerations. If desired, in any of the foregoing examples, the cells may be genetically modified to express, for example, a growth factor, an anti-apoptotic protein, or another therapeutic protein. Similarly, the proliferation, differentiation, or survival of the MSCs of the invention can be influenced by modulating the cell culture conditions including increasing or decreasing the concentration of serum in the culture medium and increasing or decreasing the plating density. Additionally, modulating the cell culture conditions includes contacting the MSCs (by adding to the culture medium) with an agent or agents that influence proliferation, differentiation, or survival. Exemplary agents include therapeutic proteins (*i.e.*, growth factors, cytokines, cell-fate determining proteins, and anti-apoptotic factors), small molecules which may agonize or antagonize the effects of any of the foregoing proteins, and pharmacological agents. In one embodiment, the MSCs are presorted prior to plating and differentiation such that only a sub-population of MSCs are subjected to the differentiation conditions. Presorting of the MSCs can be done based on expression (or lack of expression) of a gene or protein, or based on differential cellular properties including adhesion and morphology.

The MSCs display some similarities to stem cells derived from mammalian forebrain, but also possess some distinctive differences. Firstly, non-adherent clusters of the proliferating MSCs of the invention are morphologically distinct from CNS derived neurospheres. Additionally, when the MSCs of the present invention differentiate in the presence of serum, about 5-20% of the differentiated cells express neuronal markers, whereas differentiated forebrain stem cells generate only a small percentage of neurons. Moreover, significant numbers of dopaminergic neurons are found in differentiated cultures of MSCs of the present invention, whereas such neurons have not been observed in cultures of forebrain stem cells differentiated in serum. Furthermore, we have not observed any significant effects on the proliferation, differentiation or survival of the stem cells of the present invention when cultured in the presence versus the absence of LIF. Proliferating cultures of the stem cells of the present invention are additionally distinguished from CNS derived neurospheres by the expression of both nestin and fibronectin protein. Thus, the MSCs of the invention represent a novel stem cell population which can differentiate to form both neural and non-neural cell types.

Cell Therapy

The multipotent stem cells of this invention may be used to prepare pharmaceutical compositions that can be administered to humans or animals for cell therapy. The cells may be undifferentiated or differentiated prior to administration. Dosages to be administered depend on patient needs, on the desired effect, and on the chosen route of administration.

The invention also features the use of the cells of this invention to introduce therapeutic compounds into the diseased, damaged, or physically abnormal CNS, PNS, or other tissue. The MSCs thus act as a vector to transport the compound. In order to allow for expression of the therapeutic compound, suitable regulatory elements may be derived from a variety of sources, and may be readily selected by one with ordinary skill in the art. Examples of regulatory elements include a transcriptional promoter and enhancer or RNA polymerase binding sequence, and a ribosomal binding sequence, including a translation initiation signal. Additionally, depending on the vector employed, other genetic elements, such as

selectable markers, may be incorporated into the recombinant molecule. The recombinant molecule may be introduced into the stem cells or the cells differentiated from the stem cells using *in vitro* delivery vehicles such as retroviral vectors, adenoviral vectors, DNA virus vectors and liposomes. They may also be introduced into such cells *in vivo* using physical techniques such as microinjection and electroporation or chemical methods such as incorporation of DNA into liposomes. Such standard methods can be used to either transiently or stably introduce heterologous recombinant molecules into the cells. The genetically altered cells may be encapsulated in microspheres and implanted into or in proximity to the diseased or damaged tissue.

In one embodiment, the MSCs are used for the treatment of neurological disease. In another aspect the MSCs of the present invention may also be used as a source of non-neural cells, for example adipocytes, bone, cartilage, and smooth muscle cells. As an example, PCT publication WO99/16863 describes the differentiation of forebrain MSCs into cells of the hematopoietic cell lineage *in vivo*. The MSCs of the present invention are very plastic and can differentiate into neural, as well as non-neural cell types. Accordingly, the invention features methods of treating a patient having any disease or disorder characterized by cell loss by administering MSCs of the present invention (or cells derived from these cells) to that patient and allowing the cells to differentiate to replace the cells lost in the disease or disorder. For example, transplantation of MSCs and their progeny provide an alternative to bone marrow and hematopoietic stem cell transplantation to treat blood-related disorders. Other uses of the MSCs are described in Ourednik et al. (Clin. Genet. 56:267-278, 1999), hereby incorporated by reference. MSCs and their progeny provide, for example, cultures of adipocytes and smooth muscle cells for study *in vitro* and for transplantation. Adipocytes secrete a variety of growth factors that may be desirable in treating cachexia, muscle wasting, and eating disorders. Smooth muscle cells may be, for example, incorporated into vascular grafts, intestinal grafts, etc. Cartilage cells have numerous orthopedic applications to treat cartilage injuries (i.e., sports injuries), as well as degenerative diseases and osteoarthritis. The cartilage cells can be used alone, or in combination with matrices

well known in the art. Such matrices are used to mold the cartilage cells into requisite shapes.

Transplantation and delivery of MSC's and their progeny may be at the actual site of cell damage or via the blood stream.

5

Methods of Doing Business

The present invention further contemplates methods of conducting several types of businesses based on the methods and compositions of the present invention. The stem cells of the present invention provide a readily accessible
10 source of stem cells which hold tremendous therapeutic potential for a wide range of diseases and injuries. However, in order to coordinate and implement the therapeutic use of the stem cells of the invention, many issues must be addressed. These issues include providing methods of organizing and cataloging tissue, culturing stem cells harvested from that tissue, and preserving the stem cells so that
15 they can be used to treat conditions which may arise in an individual over an extended period of time. The present invention contemplates several methods of conducting businesses which aim to address these issues, and would thus vastly facilitate and improve the therapeutic use of the stem cells of the invention. The stem cells of the invention represent a readily accessible source of stem cells, and
20 thus methods of harvesting, preparing, and storing stem cells from individuals are of tremendous importance for the organized implantation of the therapeutic use of the stem cells of the present invention.

In a first aspect, the invention provides methods of preparing stem cell preparations. The method comprises obtaining an epithelial sample from an animal,
25 culturing cells dissociated from the sample using any of the methods of the invention to isolate multipotent stem cells which form non-adherent clusters, are self-renewing, express nestin and fibronectin, and differentiate into neural and non-neural cells types.

In one embodiment, the animal is a human patient, but the animal may
30 also be a laboratory animal such as a rat, mouse, pig, sheep, rabbit, dog, cat, or non-human primate. In another embodiment, the epithelial tissue may be any epithelial tissue from which the stem cells of the present invention can be isolated including

olfactory epithelium, tongue, skin, and mucosa. In a preferred embodiment, the epithelial tissue is skin.

In another embodiment, the step of culturing cells dissociated from the epithelial sample includes separating the dermal and epidermal layers of the sample.

5 In still another embodiment, the multipotent stem cells are characterized by the ability to differentiate into both ectodermal and mesodermal cell types.

In another embodiment, the multipotent stem cells can be differentiated into one or more lineage committed cell types. The differentiation of the multipotent stem cells can be influenced by modulating the plating conditions (e.g.,
10 serum concentration, plating density, addition of exogenous factors such as peptides, proteins, small organic molecules, etc.).

In any of the foregoing embodiments of this aspect of the present invention, the method of preparing the stem cells, or cells differentiated from the stem cells, may additionally include preserving the cells and storing them for later
15 use (e.g., cryogenically preserved). Furthermore, the method may optionally include formulating the cells in a pharmaceutically acceptable carrier, auxiliary or excipient.

In a second aspect, the invention provides a method for conducting a regenerative medicine business. The method comprises providing a service for accepting and logging (e.g., cataloging) epithelial tissue samples from a client. The
20 samples are then cultured using the methods of the present invention to dissociate the sample and culture multipotent cells which form non-adherent clusters, are self-renewing, and differentiate into ectodermal and mesodermal cell types. The multipotent cells can then be preserved and stored for later use by either that same patient, or by a third party.

25 In one embodiment, the multipotent cells are further characterized by the expression of nestin and fibronectin protein. In another aspect of the present invention, the epithelial tissue is selected from olfactory epithelium, tongue, skin, and mucosa. In a preferred embodiment, the epithelial tissue is skin. In yet another embodiment, the skin is selected from foreskin or skin obtained following cosmetic
30 surgery.

The second aspect of the present invention may additionally include a cell differentiation system which provides a method of differentiating the

multipotent stem cells to one or more lineage committed cell types. These differentiated cells may be preserved and stored for later use by the client or by a third party.

5 In any of the foregoing embodiments of this aspect of the invention, the method may further include a billing system for billing a client or a client's insurance provider for the isolation, cataloging, storage, and possible retrieval of the preserved stem cells or lineage committed cells differentiated from the stem cells.

10 In addition to the methods of improving the therapeutic use of the stem cells of the invention, the present invention contemplates methods of conducting a stem cells business or a drug discovery business based on using these stem cells for drug discovery and as a further research tool. The stem cells of the present invention are a readily accessible source of cells which can differentiate to both neural and non-neural cell types. Accordingly, these cells represent a valuable research tool to investigate and/or identify agents (e.g., peptides, proteins, nucleic acids, small molecule, pharmacological agents, drugs, etc.) which influence the proliferation, differentiation, migration, or survival of these stem cells. Such agents may be tested and formulated for therapeutic use (either ex vivo or in vivo) or may be used primarily for further research purposes.

20 A third aspect of the present invention provides a method of conducting a stem cell business. The method comprises identifying one or more agents which affect the proliferation, differentiation, or survival of the multipotent stem cells of the present invention. The term "agents" is meant to include nucleic acids, peptides, proteins, antisense RNAs, ribozymes, antibodies, small organic molecules, and chemical compounds. Agents can be tested individually, or libraries of agents may be tested in a high-throughput screen. Exemplary libraries include combinatorial libraries (of chemical compounds, nucleic acids, or proteins), variegated libraries, biased, and unbiased libraries. Methods of making each of these libraries are well known in the art, and one of skill in the art can select from amongst commercially available libraries or construct their own library.

30 Following the identification of one or more agents which affect the proliferation, differentiation, or survival of the multipotent stem cells of the present invention, the method further includes conducting therapeutic profiling of the

agents, or analogs of the agents for efficacy and toxicity in animals. Following such therapeutic profiling, agents which have an acceptable profile are formulated as a pharmaceutical preparation.

Therapeutic profiling and toxicity studies are critical for identifying
5 agents which not only affect stem cell proliferation, differentiation, or survival, but also for identifying those agents which may be safe and effective when administered to patients or when used to treat cells which are eventually administered to patients. Therapeutic profiling and toxicity studies are well known in the art, and are a necessary component of any drug optimization or discovery platform.

10 Before testing an experimental drug in humans, extensive therapeutic profiling (preclinical testing) must be completed to establish initial parameters for safety and efficacy. Preclinical testing establishes a mechanism of action for the drug, its bioavailability, absorption, distribution, metabolism, and elimination through studies performed in vitro (that is, in test tubes, beakers, petri dishes, etc.)
15 and in animals. Animal studies are used to assess whether the drug will provide the desired results. Varying doses of the experimental drug are administered to test the drug's efficacy, identify harmful side-effects that may occur, and evaluate toxicity.

In one embodiment, the step of therapeutic profiling includes toxicity testing of agents; analysis of pharmacokinetics and metabolism of the candidate
20 agent; and determination of efficacy in animal models. In certain instances, the method can include analyzing structure-activity relationships and optimizing lead structures based on efficacy, safety and pharmacokinetic profiles. The goal of such steps is the selection of drug candidates for pre-clinical studies to lead to filing of Investigational New Drug applications ("IND") with the FDA prior to human
25 clinical trials.

Between lead optimization and therapeutic profiling, one goal of the subject method is to develop an agent which has minimal side-effects. By toxicity profiling is meant the evaluation of potentially harmful side-effects which may occur when an effective amount of a pharmaceutical preparation is administered. A side-
30 effect may or may not be harmful, and the determination of whether a side effect associated with a pharmaceutical preparation is an acceptable side effect is made by the Food and Drug Administration during the regulatory approval process. This

determination does not follow hard and fast rules, and that which is considered an acceptable side effect varies due to factors including: (a) the severity of the condition being treated, and (b) the availability of other treatments and the side-effects currently associated with these available treatments. For example, the term cancer encompasses a complex family of disease states related to mis-regulated cell growth, proliferation, and differentiation. Many forms of cancer are particularly devastating diseases which cause severe pain, loss of function of the effected tissue, and death. Chemotherapeutic drugs are an important part of the standard therapy for many forms of cancer. Although chemotherapeutics themselves can have serious side-effects including hair-loss, severe nausea, weight-loss, and sterility, such side-effects are considered acceptable given the severity of the disease they aim to treat.

In addition to the therapeutic profiling and toxicity testing outlined above, the invention further contemplates that analogs of the identified agents may be use to affect the proliferation, differentiation, or survival of the multipotent stem cells of the present invention. The term "analog" encompasses agents which are related to the identified agents by which have been modified to improve one of more pharmacological characteristics. For example, a protein can be modified with a lipid, glycosyl, or phosphoryl moiety in order to improve serum half life or protein stability. Similarly, the stereoisomer of an identified small molecule may have improved properties. The following are example of the pharmalogical properties that can be further optimized via additional testing of the identified agents:

- Solubility
- Permeability
- Bioavailability
- Toxicity
- Mutagenicity
- Pharmacokinetics - absorption, distribution, metabolism, elimination of the agent.

Structural modifications are made to a lead compound to address issues with the parameters listed above. These modifications however, must take into account possible effects on the molecule's potency and activity. For example, if the solubility of a lead compound is poor, changes can be made to the molecule in an effort to

improve solubility; these modifications, however, may negatively affect the molecule's potency and activity.

In a fourth aspect, the present invention provides a drug discovery business. The drug discovery business comprises identifying one or more agents
5 which affect the proliferation, differentiation, or survival of the multipotent stem cells of the present invention, and licensing the rights for further drug discovery and development to a third party. As outlined in detail in the description of the third aspect of the present invention, the optimization of a potential therapeutic agent requires detailed studies. Thus, in some cases, it may be advantageous to license
10 identified agents to third parties for subsequent optimization, therapeutic profiling, and toxicity studies.

The following examples describe (i) the derivation of MSCs from postnatal and adult mouse and rat tissue, (ii) the derivation of MSCs from human
15 tissue, (iii) the differentiation of MSCs in vitro to both ectodermal and mesodermal derivatives, (iv) clonal analysis demonstrating that single MSCs are multipotent, (v) the effects of modulating culture conditions on the proliferation, differentiation, and survival of MSCs, (vi) the transformation of MSCs with exogenous DNA, (vii) the in vivo differentiation of MSCs following transplantation.

20

Example 1: Purification of MSCs from postnatal mouse olfactory epithelium

MSCs from mouse olfactory epithelium were purified as described below. Postnatal mice were stunned with a blow to the head and then decapitated. The heads were sagittally sectioned with a razor blade, and the olfactory epithelia of
25 about six postnatal (P1-P9) mouse pups were stripped from the conchae, nasal septum, and vomeronasal organs using watch-maker forceps. This tissue was placed into 3 mL of medium (DMEM/F-12 3:1) supplemented with 2% B-27 (Gibco, Burlington, Ontario, Canada), 20 ng/mL epidermal growth factor (EGF; Collaborative Research, Bedford, MA), 0.1% fungizone, and 0.5 mL/100mL
30 penicillin/streptomycin (Gibco). Following collection, the epithelia were teased apart with watchmaker forceps, releasing a large number of single cells and small cell clusters. The cell suspension was transferred to a 15 mL tube, and 7 mL of

additional medium was added. The clusters were dissociated into single cells by manual titration with a 10 mL plastic pipette and passed through a 60 micron filter (Gibco). Typically, dissociated cells from the olfactory epithelia from six pups were plated into two 50 mL tissue culture flasks and cultured in a 37 °C, 5% CO₂ tissue culture incubator. Two days later, most cells in the cultures were dead or dying. A small number (less than 1% of the initial cell number) of large, phase bright cells were present, however, most of which were attached to the flask bottom. Over the next two to six days, these cells divided and produced spherical clusters, which became larger over time. At four to five days in culture, there were approximately 500 clusters of dividing cells per pup used in the original purification. Most of these cell clusters detached from the flask surface over the next few days. These non-adherent cell clusters continued to grow and fused together to become macroscopic, reaching approximately 100 µm in diameter following 10 DIV. After 12 DIV, the non-adherent cell clusters became macroscopic, reaching approximately 200 µm or greater in diameter.

If EGF was not added to the medium, small clusters of dividing cells were still seen by 4 DIV, indicating that the cells themselves were producing trophic factors in quantities that, in some cases, was sufficient to maintain their proliferation.

Greater than 95% of the cells in the dividing clusters expressed nestin, a marker for stem cells and neural stem cells. These nestin-positive cells could be repeatedly passaged, indicating that the cells were stem cells. Six days after purification, the medium (5 mL) was removed from the flasks. This medium contained many clusters of non-adherent stem cells that had detached from the flask surface. The detached cells clusters were manually triturated with a fire-polished pipette, thereby dissociating many of the cell clusters into single cells. The medium containing the cells was then placed in a second flask with an additional 15 mL of fresh medium (total volume = 20 mL). After a further six days, one quarter of the medium was removed and the non-adherent clusters of cells were again triturated and transferred to a new flask with 15 mL fresh medium. These cells have been successfully passaged more than twenty times without losing their multipotency.

Example 2: Differentiation of mouse MSCs into neurons, astrocytes and

oligodendrocytes After the cellular clusters of Example 1 had been generated, they could be differentiated into neurons, astrocytes, and oligodendrocytes. Clusters from cultures 7 to 14 days after purification were plated onto polylysine coated 35 mm culture dishes or 4 multiwell culture dishes, in DMEM/F12 media containing 2% fetal bovine serum (Hyclone, Logan, UT) and 2% B-27 (containing no EGF). The medium was changed every three to four days. Over the next six to nineteen days, cells migrated out of the clusters onto the dish surface. Some of these cells had the morphology of neurons, astrocytes, or oligodendrocytes. We determined the phenotype of these cells using the following antibodies: GFAP for astrocytes; neurofilament 160 (NF-160), MAP-2, β III tubulin, and NeuN for neurons; and GC for oligodendrocytes. Antibodies to tyrosine hydroxylase (TH) were used to identify dopaminergic, noradrenergic, and adrenergic neurons. Dopamine -hydroxylase (DBH) was also used for noradrenergic and adrenergic neurons.

Astrocytes, neurons, and oligodendrocytes were all found to differentiate from the MSCs of this invention, indicating that the cells were multipotent. We also cultured MSCs from transgenic mice which express β -galactosidase off of the neuron specific T1 α -tubulin promoter, which allowed us to use staining with the ligand X-gal or antibodies for β -galactosidase as an additional neuronal marker.

We observed β -galactosidase-positive cells.

Since the majority of differentiated cells remained in clusters, it was not possible to determine the percentage of cells expressing each marker. The majority of cells that migrated out of the clusters were GFAP positive, while a large number of cells were either NeuN or β -galactosidase positive. A lower number of cells were GC positive. Therefore the MSCs could differentiate into neurons, astrocytes and oligodendrocytes. TH-positive cells were also identified. These TH-positive cells are most likely dopaminergic neurons and not noradrenergic or adrenergic neurons, since no cells were found to be DBH positive. Significantly, no TH, GFAP or GC positive cells have ever been reported *in vivo* in the nasal epithelium.

Therefore the olfactory epithelium-derived nestin-positive MSCs are capable of differentiating into cell types (*e.g.*, oligodendrocytes, astrocytes, GABAergic neurons, and dopaminergic neurons) never found in the olfactory epithelium.

Like the originally-purified olfactory MSCs, MSCs passaged from two to twenty times could also differentiate into neurons, astrocytes, and oligodendrocytes. MSCs which had been passaged were plated on polylysine-coated dishes. Cells migrated from the clusters and spread out over the surface of the dish. After 16 DIV, cells that were immunopositive for GC, GFAP, β III tubulin, NeuN, lacZ, or TH could be identified. Moreover, the proportion of cells positive for the various markers was similar to that seen in the differentiated cultures from the original cultures.

10 Example 3: Purification of MSCs from olfactory epithelial tissue of adult mice and rats

Similar to the foregoing results, MSCs were also purified from adult mouse and rat olfactory epithelium and vomeronasal organ using the methods described in Examples 1 and 2.

15 Adult mice and rats were anaesthetized with an overdose of somnitol, and then decapitated. The olfactory and vomeronasal organ epithelia were stripped from the conchae and nasal septum and incubated in DMEM/F12 medium for one to two days after their dissection and prior to the rest of the purification procedure. After this incubation, the epithelia were dissociated in an identical manner as the
20 epithelia from juvenile mice. Two days after the isolation, the majority of the cells were dead with the exception of a very few large phase bright cells. These cells divided over the next few days, forming small clusters of dividing cells similar to those described in Example 1. These small clusters grew to give rise to the large clusters that detached from the culture dish surface. After approximately six
25 divisions, cells in some of these clusters began to differentiate and spread out over the flask's surface, while some other clusters, which had been floating, reattached to the surface and then produced differentiated cells. In some cases, cells multiplied to produce small clusters of cells, but did not grow to form large cell clusters like the postnatal cultures. We have passaged these cells twenty times using the same
30 procedure as that described above with respect to the cells purified from juvenile olfactory epithelium. These proliferating cells from the adult were also nestin-positive.

After the cell clusters derived from adult tissue had been generated, the cells could be differentiated into neurons, astrocytes, and oligodendrocytes. Seven days after isolation, clusters were plated onto polylysine-coated 35 mm culture dishes or multi-well culture dishes, in medium containing 2% fetal bovine serum and 2% B-27, but no EGF. Over the next month, cells migrated from the cell clusters and onto the dish surface. We determined the phenotype of these cells using antibodies to astrocytes, neurons, dopaminergic neurons, and oligodendrocytes as described above.

Neurons (including dopaminergic neurons), astrocytes, and oligodendrocytes were found, although the number of these cells was much lower than the number obtained from the juvenile. The cells purified from adult olfactory epithelia are self-renewing and multipotent, and thus are MSCs.

Example 4: Purification of MSCs from mouse tongue

We derived MSCs from the tongue, another peripheral tissue that contains sensory receptors. The tongue was dissected to remove the epithelial layer that contains the sensory receptors and their underlying basal cells. This layer of tissue was triturated to produce single cells and the single cells were plated in flasks containing DMEM/F12 media supplemented with B-27 and EGF, TGF , and/or bFGF, as described for the olfactory epithelium. After two to three days in a 37 °C, 5% CO₂ tissue culture incubator, greater than 99% of the cells in the culture were dead or dying. A small number (less than 1%) of large phase-bright cells were present, however, most of which attached to the flask bottom. Over the next two to six days, these cells divided and produced spherical clusters that became larger over time and detached from the flask surface. The cells in these clusters were nestin-positive.

These nestin-positive MSCs can be passaged using the same techniques as used for the multipotent stem cells derived from the olfactory epithelium. Similarly, the MSCs can be differentiated into neurons, astrocytes and oligodendrocytes using the techniques described herein.

Example 5: Purification of MSCs from mouse skin

Skin from neonatal mice aged 3-15 days was dissociated and cultured in uncoated flasks containing 20 mg/mL EGF and 40 mg/mL bFGF. Over the subsequent one to five days, many (>90%) of the cells die. A small population of cells hypertrophy and proliferate to form small cell clusters growing in suspension. Some of these cells first attach to the tissue cluster plastic, hypertrophy and proliferate, and then detach as the clusters become of sufficient size. Other cells never attach to the tissue culture plastic and instead proliferate in suspension from the beginning. After four to five days, the cell clusters are small but easily distinguishable as clusters of non-adherent, proliferating cells. By seven to ten days, many of the cell clusters reach diameters of as much as 100 μ m, while by two weeks, the cell clusters are macroscopic if left unperturbed. Many cells adhered to the plastic, and many died, but by about three to seven days, suspended, non-adherent clusters of up to about 20 cells formed. These suspended or floating cells were transferred to a new flask seven days after initial culturing; again, many cells adhered, but the cells in the floating clusters proliferated to generate larger clusters of more than about 100 cells (Fig. 1A, top panel). These larger clusters were then isolated, dissociated and passaged. By this process of selective adhesion, substantially pure populations of floating clusters were obtained after 3 to 4 weeks. Cells that generated these clusters were relatively abundant; 1.5 to 2 cm² of abdomen skin was sufficient to generate six 25 cm² flasks of floating clusters over this period of time.

To determine whether clusters contained MSCs, we dissociated the clusters and plated the cells onto poly-D-lysine/laminin-coated dishes or chamber slides without growth factors and, 12 to 24 hours later, immunostained them for the presence of the neural precursor-specific marker nestin. After three passages, the majority of the cells expressed nestin (Fig. 1B, top panel), a property they maintained over subsequent passages. They did not, however, express the p75 neurotrophin receptor, a marker for neural crest stem cells, as detected either by immunocytochemistry or western blots. Additionally, they are negative, as detected by immunocytochemistry, for two proteins characteristic of mesenchymal stem cells: vimentin and cytokeratin.

We also determined whether the skin-derived MSCs expressed fibronectin. Four lines of skin-derived MSCs cultured from either adult (Fig. 2; left two columns) or neonatal (right two columns) mouse skin, cultured for either long term (first and third columns) or short term (second and fourth columns) were each dissociated, plated for two days in DMEM/F12 (3:1) containing 2% B-27 supplement, and then immunostained for nestin and fibronectin. As is demonstrated in Fig. 2, the majority of cells expressed both markers.

To determine whether clusters of cells could be generated from adults, skin of adult mice was dissociated and cultured as described above. Similar to neonatal mouse skin, most cells adhered to the flask or died when first cultured. After three to seven days, however, clusters of up to approximately 20 cells were observed that subsequently increased in size. When these cells were passaged at least three times (Fig. 1A, bottom panel), and plated onto poly-D-lysine/laminin overnight in the absence of growth factors, they too were immunopositive for nestin (Fig. 1B, bottom panel) and fibronectin (Fig. 2). The nestin-positive cells from adults and neonates have been passaged in this manner for over 30 passages, during which time the number would have theoretically expanded at least 10^9 -fold (assuming a doubling time of approximately one week).

To determine whether these nestin-positive, fibronectin-positive cells from skin could generate neural cell types, we analyzed neonatal skin-derived cells after three or more passages and greater by plating them on poly-D-lysine/laminin in the absence of growth factors. Immunostaining (Figs. 1C and 1D) and western blot analysis (Fig. 3A) revealed that the skin-derived cells expressed neuronal markers. At seven days, a subpopulation of morphologically-complex cells coexpressed nestin and neuron-specific β III-tubulin, a profile typical of newly-born neurons (Fig. 1C). At later time points of 7-21 days, cells also expressed neurofilament-M (NF-M) (Figs. 1D, 3A), neuron-specific enolase, and NeuN, three other neuron-specific proteins. Finally, some neurofilament-positive cells expressed GAD (Fig. 1D), a marker for GABAergic neurons, which are not found in the PNS. Similar results were obtained for adult skin-derived MSCs, although at early passages some of the β III-tubulin and neurofilament-positive cells were less typically neuronal in morphology.

Immunostaining and western blots revealed that both neonatal and adult MSCs generated cells expressing the glial markers GFAP and CNPase at seven to twenty-one days after plating (Figs. 1D-1F, 2A). Double-labeling for these proteins demonstrated the presence of (i) cells that were GFAP- positive but not CNPase-
5 positive (potentially astrocytes), (ii) cells that expressed CNPase but not GFAP (potentially oligodendrocytes or their precursors), and (iii) a small subpopulation that were bipolar and expressed both CNPase and GFAP (potentially Schwann cells) (Fig. 1E). A subpopulation of GFAP-positive cells also expressed nestin, a finding previously reported for developing CNS astrocytes. Additionally, some cells were
10 positive for A2B5, a marker for oligodendrocyte precursors (Fig. 4). Like GAD-positive neurons, astrocytes and oligodendrocytes are normally found only in the CNS.

Double-labeling studies supported the following additional conclusions. First, glial versus neuronal markers were expressed in distinct subpopulations of
15 MSCs progeny. Second, after twenty passages, skin-derive MSCs were still able to differentiate into neurons and glial cells. Finally, skin-derived MSCs were able to generate smooth muscle cells (as determined by both expression of smooth muscle actin (SMA) and morphology; Fig. 1G), adipocytes (Figs. 5 and 6), cartilage, bone, cardiac muscle, and skeletal muscle.

20

Example 6: MSCs originate from the dermal layer of the skin

The two major layers of the skin are the epidermis and the dermis. To determine the origin of the skin-derived MSCs, we dissected and cultured P7, P14, and P18 mouse epidermis and dermis. The two layers of the skin were separated by
25 incubating the skin pieces (1 X 2 cm²) in 0.2% trypsin at 40 °C for about 24-36 hours, or until the dermis could be separated from the epidermis. The cells in each layer were dissociated separately and then cultured in DMEM/F12 (3:1) with B-27 supplement, EGF (20 ng/mL) and FGF (40 ng/mL). Only the cells derived from the dermis generated clusters of cells similar to those derived from whole skin (Fig. 7A).
30 No viable cells were obtained from the epidermis. To characterize the dermis-derived cell clusters, the clusters were cultured for four weeks and then plated onto tissue culture chamber slides coated with poly-D-lysine and laminin. After 24

hours, the cells were then processed for immunocytochemistry. Like MSCs derived from whole mouse skin, the dermis-derived cells coexpressed nestin and fibronectin (Fig. 7B).

5 Example 7: Clonal analysis indicates that skin-derived MSCs are multipotent

To determine whether skin-derived MSCs are multipotent, we isolated single cells by limiting dilution of cells from clusters that three months prior had been derived from neonatal mice. We cultured the cells for five weeks in medium from the same culture line and containing growth factor, and then differentiated the
10 cells for two weeks in medium lacking growth factor but containing 3% rat serum. The cells were then processed for immunocytochemistry. As is demonstrated in Fig. 8, single clones of cells contained NF-M- and CNPase-positive cells (Fig. 8A), and GFAP- and CNPase-positive cells (Fig. 8B).

15 Example 8: Western blot analysis of skin-derived MSCs

For western blot analysis of skin-derived MSCs, four cultures (one adult-derived line and three neonate-derived lines) that had been passaged from seven to 40 times were analyzed either as clusters or following differentiation by plating in medium containing 1% FBS, B-27 supplement, and fungizone for 14 days in 60 mm
20 dishes coated with poly-D-lysine and laminin. Cell lysates were prepared, and equal amounts (50-100 µg) of protein from each culture were separated on 7.5% or 10% polyacrylamide gels, transferred to membrane, and then probed with anti-nestin monoclonal antibody (1:1000; Chemicon), anti NF-M polyclonal antibody (1:1000; Sigma), anti GFAP polyclonal antibody (1:1000, Dako), or anti fibronectin
25 polyclonal antibody (1:1000; Sigma). As positive controls, we used cortical progenitor cells cultured in the presence of CNTF (which results in astrocytic differentiation) or in the absence of CNTF (which results in neuronal differentiation) and adult mouse cortex. As negative controls, we used sympathetic neurons and liver. As illustrated in Fig. 9A, western blotting confirmed the expression of GFAP
30 and NF-M in cultures differentiated from both adult and neonate skin-derived MSCs. Similarly, Fig. 9B illustrates the expression of both nestin and fibronectin in adult and neonate skin-derived MSC clusters.

Example 9: MSC differentiation can be modulated by plating conditions

As is illustrated above, when clusters of skin-derived MSCs are dissociated and plated in medium containing FGF and EGF, most of the nestin-positive cells become neurofilament-positive. We have found that when the cells are plated in medium containing 10% FBS, the cells adopt a morphology similar to that displayed by adipocytes. The adoption of the adipocyte cell fate was confirmed by staining with Oil Red O (Fig. 5). The ability of 10% FBS to induce adipocyte differentiation was true for both adult and neonate skin-derived MSCs (Fig. 6).

This example demonstrates both the ability of skin-derived MSCs to differentiate to mesodermal cell types, and the significant effects of plating conditions on the proliferation, differentiation and survival of skin-derived MSCs. In addition to serum concentration, other plating conditions can be altered to influence the proliferation, differentiation, and survival of these cells. Such plating conditions include plating density, the addition of pharmacological agents to the culture media (i.e., pharmacological inhibitors,), the addition of therapeutic protein(s) to the culture media (i.e., growth factors, cytokines, anti-apoptotic proteins), and the addition of small molecules that agonize or antagonize the function of a protein(s) and/or modulate signaling through a signal transduction pathway important in regulating the proliferation, differentiation, or survival of the skin-derived MSCs. These parameters can be altered individually, or in combination to influence the proliferation, differentiation or survival of the skin-derived MSCs. For example, one or more therapeutic proteins can be added to the culture media. Furthermore, therapeutic proteins can be added in combination with changes in plating density. Still another embodiment combines the addition of therapeutic protein(s) with the addition of a small molecule. Additional plating conditions include the co-culture of the skin-derived MSCs with other cells or cell types, and the pre-sorting of the skin-derived MSCs prior to plating.

Examples of the effects of altering several different plating conditions are presented below.

Example 10: Pharmacological inhibitors affect survival and proliferation of skin-derived MSCs

When skin-derived MSCs are plated for three days in proliferation medium containing FGF, they typically exhibit a spherical morphology characteristic of their proliferative state (Fig. 10). We tested the ability of pharmacological agents to alter this phenotype. Supplementing the medium with PD098059 (an inhibitor of the ERK MAPK pathway) caused proliferating cells to flatten and differentiate (Fig. 10), while supplementing with LY294002 (an inhibitor of the PI-3-K pathway), caused the cells to die (Fig. 10). The p38 MAPK inhibitor SB203580 had no observed effect on the proliferating skin-derived MSCs.

These and other pharmacological agents could be added to the culture media to influence cell proliferation, differentiation, and survival. Pharmacological agents can be added alone or in combination, and combinations of agents can be co-administered or administered at different times. Additionally, pharmacological agents can be administered in combination with one or more therapeutic proteins or small molecules to influence cell proliferation, differentiation, and survival. Such combinations of pharmacological agents and therapeutic proteins can be co-administered or administered at different times to influence cell proliferation, differentiation, and survival.

Example 11: Purification of nestin-positive cells from adult human skin

We have purified nestin-positive cells from human scalp. To purify MSCs from human skin, we utilized tags of scalp tissue generated by placement of a stereotactic apparatus during neurosurgery. Scalp tags totalling 1 cm² or less from each of eight individuals were used. The skin included dermal and epidermal tissue. Tissue was cut into smaller pieces that were then transferred into HBSS containing 0.1% trypsin for forty minutes at 37 °C. Following trypsinization, tissue samples were washed twice with HBSS and once with DMEM:F12 (3:1) supplemented with 10% rat serum to inactivate the trypsin. Trypsinized tissue was then mechanically dissociated by trituration in a pipette and the resulting dispersed cell suspension was poured through a 40 µm cell strainer into a 15 mL tube. The tube was then centrifuged for five minutes at 1000 rpm (~1200 X g). The cells were resuspended

in DMEM:F12 medium containing 40 ng/mL bFGF, 20 ng/mL EGF, 2% B-27 supplement, and antibacterial and antifungal agents, and then cultured in 12 well plastic tissue culture plates. Every seven days, the cell clusters are harvested by centrifugation, triturated with a fire-polished pasteur pipette, and cultured in fresh
5 medium.

As for the use of rodent skin, most cells (>75%) adhered to the plastic or died, but after seven days, small floating clusters of cells were observed. These clusters were then partially dissociated and transferred to new wells, where they slowly increased in size. After additional passaging, clusters were plated on poly-D-
10 lysine/laminin in 3% FBS with no growth factors, and analyzed for the presence of neural markers.

Within two weeks, greater than 30% of the cells within the cell clusters were nestin-positive. Immunolabeling of four to six week old cultures also revealed that many of the cells in the clusters were nestin-positive with the percentage
15 varying from less than 50% to greater than 80% two to three days after plating, and that greater than 70% of the cells were fibronectin positive. Double-label immunocytochemistry at the same or longer time-points revealed that, in all cultures, some nestin-positive cells also expressed β III-tubulin and displayed elongated neurites. Thus, adult human skin is a source for nestin-positive and fibronectin
20 positive MSCs cells that, when differentiated, can express neuron-specific proteins.

Example 12: Purification and differentiation of MSCs derived from other human peripheral tissues containing sensory receptors

MSCs can be purified from human olfactory epithelium using the same
25 procedures as described for the purification of stem cells from rodent olfactory epithelium. Source material is acquired by surgical removal of olfactory epithelial tissue from the donor. Because the MSCs are capable of proliferation and self-renewal, little source tissue is required. Preferably, the amount is at least about 1 mm³. Conditions for culturing human cells are described in Example 11, above.
30 Other conditions are known to those skilled in the art, and can be optimized for proliferation or differentiation of neural stem cells, if desired.

We can purify MSCs from other peripheral tissues containing sensory receptors, other than the olfactory epithelium, tongue, and skin, using techniques described herein. Passaging and differentiation of these cells is also performed using the same techniques described herein. Other peripheral tissues containing sensory receptors include, for example, mucosal membranes from the mouth or reproductive system.

Example 13: Transformation of MSCs

In therapy for neurodegenerative diseases, it may be desirable to transplant cells that are genetically modified to survive the insults that caused the original neurons to die. In addition, MSCs may be used to deliver therapeutic proteins into the brain of patients with neurodegenerative disorders to prevent death of host cells. Exemplary therapeutic proteins are described herein. In still another example, MSCs can be induced to differentiate into a desired cell type by transfecting the cells with nucleic acid molecules encoding proteins that regulate cell fate decisions (*e.g.*, transcription factors such as Isl-1, en-1, en-2 and nurr-1, implicated in regulating motoneuron and striatal phenotypes). Using such a method, it is possible to induce the differentiation of the specific cell types required for transplant therapy. Therefore, it would be advantageous to transfect MSCs with nucleic acid molecules encoding desired proteins. We have previously used recombinant adenovirus to manipulate both postmitotic sympathetic neurons and cortical progenitor cells, with no cytotoxic effects. We now have established that olfactory epithelial-derived MSCs and skin-derived MSCs can each be successfully transfected with high efficiency and low toxicity. MSCs can be transfected either transiently or stably using not only adenoviral mediated methods, but also using lipofectamine or electroporation.

Example 14: Differentiation of MSCs into the appropriate cell type *in vivo* following transplantation into adult rodent brain

One therapeutic use for the MSCs of the present invention is autologous transplantation into the injured or degenerating CNS or PNS to replace lost cell

types and/or to express therapeutic molecules. We demonstrate below that the MSCs can differentiate into neurons when transplanted into the adult brain.

If desired, the dopaminergic innervation of the adult striatum can be unilaterally destroyed by a local infusion of 6-hydroxydopamine under conditions in which noradrenergic neurons are spared. Several weeks later, MSCs are
5 transplanted into both the intact and lesioned striatum. Alternatively, the cells can be transplanted into unlesioned animals. The fate of the transplanted MSCs is then determined by immunohistochemistry. Exemplary transplantation studies are described below. These studies demonstrate that transplanted MSCs can
10 differentiate into neurons *in vivo*, as they can *in vitro*. In the former case, differentiation and cell fate choice is controlled by the local environment into which each cell is placed. Both *in vitro*-differentiated and undifferentiated cells are useful therapeutically in the treatment, for example, of neurodegenerative disease (*e.g.*, Parkinson's disease and multiple sclerosis) or spinal cord injury. For example,
15 dopaminergic neurons differentiated from MSCs, or the MSCs themselves, may be transplanted into the substantia nigra or the striatum of patients having Parkinson's disease. If desired, the MSCs may also be genetically-modified to express a desired protein. Such genetic modification may help influence the proliferation, differentiation, and survival of the MSCs. In one embodiment, the genetic
20 modification protects the transplanted cells from the conditions which caused the degeneration of the endogenous cells.

In one example, the dopaminergic innervation to adult rat striatum was first unilaterally lesioned with the chemotoxin 6-hydroxydopamine, and the efficacy of the lesions was tested two weeks later by amphetamine-induced rotational
25 behavior. Two days prior to transplantation, rats were immunosuppressed with cyclosporin. MSCs, produced from olfactory epithelia as described herein, were then stereotactically injected into the caudate-putamen complex on both the lesioned and unlesioned sides. Sixteen days following transplantation, animals were sacrificed, and sections of the striatum were analyzed for nestin- and TH-
30 immunoreactivity. Five of eight animals received successful injections of MSCs in the striatum. Of these, four animals showed evidence of a nestin-positive tract on both the lesioned and unlesioned sides, although tracts on the lesioned side appeared

to be more intensely nestin-immunoreactive. On adjacent sections, TH-positive cells were observed confined to an area close to the transplant tract on both the lesioned and unlesioned side. As many as 25-30 TH-positive cells were identified on each section. Cell morphology varied from small, round cells lacking processes to neurons that were morphologically complex with multiple fine processes. In some cases, the processes of these TH-positive neurons extended into the striatum for distances of up to 300 μm .

To confirm that these TH-positive neurons derived from the MSCs, we performed two sets of experiments in which the transplanted cells were detectably-labeled. In one set of experiments, transplanted MSCs were derived from T 1:nlacZ transgenic mice, in which the neuron-specific T 1 α -tubulin promoter drives expression of a nuclear-localized β -galactosidase marker gene. Immunohistochemical analysis of animals receiving the transgenic MSCs revealed the presence of β -galactosidase-positive neurons within the transplant tract, confirming that the transplanted MSCs generated neurons *in vivo*, as they did *in vitro*. In a second set of experiments, MSCs were labelled with BrdU for 18 hours, washed to remove the BrdU label, and then transplanted unilaterally into the 6-hydroxydopamine-lesioned striatum of animals (10 rats, 4 mice) prepared as described herein. Immunohistochemical analysis with an anti-BrdU antibody revealed that all animals showed evidence of BrdU-positive transplant tracts. Immunocytochemistry with anti-GFAP revealed that, in both xenografts and allografts, GFAP-positive cells with heterogeneous morphology were concentrated at the transplant site, but were also present in moderate amounts over the entire ipsilateral hemisphere, with additional scattered reactive astrocytes seen in the contralateral hemisphere. GFAP-BrdU double-labelled cells were present mainly within or close to the transplant tract, and varied in morphology from small, round cells with only a few processes, to large polygonal or fusiform cells with multiple processes. Immunohistochemistry with anti-TH revealed that TH-BrdU double-labeled cells were also present, although these were few in number relative to GFAP-BrdU positive cells. BrdU-TH double-labeled cells were mainly small to medium-sized without processes, although some examples of double-labeled cells with processes were found within and adjacent to, the transplant tract. Thus, MSCs

generated astrocytes and neurons *in vivo*, and a subpopulation of the latter were TH-positive. Together, these findings show that peripheral tissue-derived MSCs are capable of generating cell types that are never found within olfactory tissue, including oligodendrocytes and TH-positive neurons.

5 To determine whether skin-derived MSCs also generate differentiated neural cell types *in vivo*, we tagged adult mouse skin-derived MSCs with (i) BrdU, and (ii) a recombinant adenovirus expressing GFP, and then transplanted them as cell clusters of about 20 to about 100 cells into the lateral ventricles of P2 rats. Immunostaining fourteen days later revealed that, in all animals analyzed (n=8),
10 transplanted cells had migrated extensively (Fig. 11A). In particular, tagged cells had integrated into the cortex, the hypothalamus and the amygdala in all, and into the hippocampus in two of the transplanted brains (Fig. 11A). In the cortex, GFP-positive cells were located in patches (Figs. 11A, 11B) or occasionally as single cells (Fig. 11C), including some that had integrated into and adopted the morphology of
15 layer V pyramidal neurons (Figs. 11B, 11C). These cells had triangular-shaped soma, and projected a presumptive apical dendrite from layer V towards layer I, in a manner similar to the endogenous layer V neurons. That these cells were neurons was demonstrated by double-labeling for neuron-specific enolase (Fig. 3D). Immunocytochemical analysis also confirmed that these were transplanted cells, as
20 BrdU-positive cells were present in the same locations as GFP-positive cells in all brains (Fig. 11B).

 In both the amygdala and hippocampus, transplanted cells also displayed neuronal morphology. In the amygdala, GFP and BrdU-positive cells were large, with prominent nuclei, and extensive processes (Fig. 11E). In the hippocampus,
25 transplanted cells had integrated into both the dentate gyrus and pyramidal cell layers, and their morphology was typical of the endogenous granule and pyramidal cells, respectively (Figs. 11A, 11E). GFP-positive staining was also seen within the molecular layer. Finally, GFP- and BrdU-positive cells were observed in other locations, such as the hypothalamus, where the morphology of many cells was not
30 typically neuronal.

 Skin-derived MSCs transplanted into adult rats also survive and integrate. We labeled adult mouse skin-derived MSCs that had been passaged more than thirty

times with the nuclear dye 33258, washed extensively, and then injected the cells stereotactically into the brains of adult rats that were immunosuppressed with cyclosporin. Four weeks later, we sacrificed the animals by perfusion and processed the brains for histological examination. Hoeschst-labeled cells were present in the hippocampus, olfactory bulb, and striatum. From these data, we conclude that the transplanted skin-derived MSCs are capable of survival following transplantation. Moreover, cells are capable of migrating from the site of injection to numerous brain regions.

Skin-derived MSCs are also capable of survival, migration, and integration following transplantation into a hemisected adult mouse spinal cord. In this example, the cells were injected into the injured sides of hemisected spinal cords. Eight days later, the animals were sacrificed and the spinal cords processed for histological analysis. Hoechst-labeled cells were present at the site of the initial injection, and had also migrated extensively into the injured spinal cord.

15

Example 15: Differentiation of non-neural cells from MSCs

In addition to being capable of differentiating as neural cells (*i.e.*, neurons, oligodendrocytes, astrocytes, and Schwann cells), the peripheral tissue-derived MSCs are capable of differentiating as non-neural cells that are normally not found in the tissue from which the cells were derived. For example, we have demonstrated that the skin-derived MSCs can differentiate as smooth muscle cells, cartilage, bone, muscle, and adipocytes. It is likely that the cells described herein have even greater potential. Conditions for the differentiation of the MSCs into smooth muscle cells, adipocytes, cartilage, bone, skeletal muscle, and cardiac muscle are described herein. Additionally, we show that the skin-derived MSCs can express RNA transcripts consistent with endodermal differentiation. These findings demonstrate that the skin-derived MSCs have potential to differentiate along all three germ layers.

Signals or conditions sufficient for inducing MSCs to differentiate as other cell types (*e.g.*, lymphocytes, cardiac muscle cells, skeletal muscle cells, melanocytes, and pancreatic cells) are known in the art. For example, unique signals induce neural crest-derived stem cells to become melanocytes, cartilage, smooth

muscle cells, or bone (for review, see LaBonne and Bronner-Fraser, J. Neurobiol., 36:175-189, 1998; Sieber-Blum, Intl. Rev. Cytol. 197:1-33, 2000). Conditions for inducing CNS-derived neural stem cells to differentiate as non-neural cells such as smooth muscle cells, skeletal muscle cells, hepatocytes, hematopoietic cells, osteocytes, and chondrocytes have similarly been elucidated (Bjornson et al., Science 283:534-537, 1999; Tsai and McKay, J. Neurosci. 20:3725-3735, 2000; Keirstead et al., J. Neurosci. 19:7529-7536, 1999; Mujtaba et al., Dev. Biol. 200:1-15, 1998; Clark et al., Science 288:1660-1663, 2000).

Our recent discovery that MSCs maintain the potential to produce both neural and non-neural cell types has been accompanied by the discovery that non-neural stem cells such as bone marrow-derived stem cells (*i.e.*, stromal cells or mesenchymal stem cells) also have the potential to produce a wide variety of neural and non-neural stem cells (Ferrari et al., Science 279:1528-1530, 1998; Gussoni et al., Nature 401:390-394, 1999; Peterson et al., Science 284:1168-1170, 1999; Pereira et al., Proc. Natl. Acad. Sci. USA 92:4857-4861, 1995; Prockop, Science 276:71-74, 1997; Kessler and Byrne, Annu. Rev. Physiol. 61:219-242, 1999; Pittenger et al., Science 284:143-147). The peripheral tissue-derived MSCs described herein can be induced to differentiate into both neural and non-neural cells that are not normally found in the tissue from which the MSCs were derived.

a. *MSCs can differentiate to smooth muscle:* For induction of differentiation

into smooth muscle cells, the cell clusters were centrifuged, the growth factor-

containing supernatant removed, and the clusters resuspended in fresh media

containing B-27 supplement and either 3% rat serum or 1-3% fetal bovine serum.

The clusters were then plated onto dishes coated with poly-D-lysine/laminin, and

the medium was changed every 3 to 7 days. Smooth muscle cells were identified by

immunocytochemistry with an antibody to smooth muscle actin (SMA).

b. *MSCs can differentiate to adipocytes:* For induction of differentiation into adipocytes, the cell clusters were centrifuged, the growth factor-containing supernatant removed, and the clusters resuspended in fresh media containing B-27 supplement with 10% fetal bovine serum. The clusters were plated onto dishes coated with D-lysine/laminin. Differentiated adipocytes were identified by OilRed staining.

c. *MSCs can differentiate to a skeletogenic fate:* For induction of differentiation along a skeletogenic lineage, the cell clusters were centrifuged, the growth factor containing supernatant removed, and the clusters resuspended in fresh media containing B-27 supplement with 15% fetal bovine serum including skeletogenic supplements. The skeletogenic supplement includes dexamethasone (100 nM), ascorbic acid (50 nM), and β -glycerophosphate (10 mM). After 2 weeks, Alcian Blue staining of the cultures reveals nodules of staining characteristic of chondrocytes. Alcian Blue staining indicates that the chondrocytes produce acidic proteoglycans (Figure 13). After 3 weeks, calcium accumulation is observed in the cultures indicative of osteoblast activity. The calcium accumulation is assayed by Alizarin Red S staining (Figure 14). Alcian Blue/Alizarin Red co-staining at 3 weeks demonstrates that the calcium accumulation occurs within a layer of chondrocytic proteoglycans (Figure 15). Finally, by about 4-5 weeks, optically dense deposits, indicative of bone formation, are observed in the culture (Figure 16).

d. *MSCs can give rise to muscle:* To assess the ability of the skin-derived stem cells of the invention to differentiate along a muscle lineage, we co-cultured GFP-labelled skin-derived stem cells with either cardiac myocytes or with C2C12 skeletal myoblasts. After several days of co-culture the skin-derived stem cells were analyzed based on both morphology and on protein expression. Cells co-cultured with cardiac myocytes express fetal cardiac actin, and the fetal cardiac actin expression co-localizes with GFP (indicating that the expressing cells are derived from the skin-derived precursors) (Fig. 17). Fetal cardiac actin is expressed in both cardiac and skeletal muscle, and the morphology of these cells is consistent with either

two cardiac muscle cells or with a single multinucleated skeletal myotube. However these results indicate that skin-derived stem cells can differentiate to a muscle cell type. Cells co-cultured with C2C12 cells give rise to desmin positive cells, and desmin expression co-localizes with GFP (Fig. 18). The morphology and protein expression of the skin-derived stem cells cultured in this manner is consistent with their differentiation to skeletal muscle. These experiments indicate that skin-derived stem cells can differentiate to produce skeletal muscle, and likely can also differentiate to produce cardiac muscle. Additionally, we conducted a series of experiments which demonstrate that skin-derived stem cells can differentiate to produce multi-nucleate muscle tissue without the need to co-culture the cells with other cell types. Briefly, skin-derived stem cells were subjected to a two step differentiation protocol. In the first step, the cells were cultured for 24 hours in differentiation media supplemented with serum and 5-azacytidine. In the second step, 5-azacytidine was removed from the media and replaced with hydrocortisone. Skin-derived stem cells differentiated to form multi-nucleate tissue characteristic of muscle. These cells also express muscle specific markers including desmin and myosin fast protein.

e. MSCs can express endodermal markers: We have shown that the skin-derived MSCs of the invention can differentiate to give rise to both neural and non-neural cells. We have presented six examples of mesodermal cell types that arise from differentiation of the MSCs. We now present evidence that the MSCs can also express transcripts consistent with endoderm differentiation. Figure 19 shows RT-PCR analysis demonstrating that MSCs express the endodermal marker GATA-4. In a second experiment, skin-derived MSCs were cultured under standard proliferation conditions in the presence or the absence of B-27 supplement. Cells were dissociated and plated in media supplemented with nicotinamide. Differentiated cells were analyzed by RT-PCR for the expression of several endodermal markers including GATA-4, HNF3 α , Isl1, AFP, HNF3 β , Ngn3, Pdx-1, and Insulin. Figure 20 summarizes the results of this experiment which demonstrates that

cells differentiated in the presence of nicotinamide express markers of endodermal differentiation. Additionally although endodermal differentiation is observed in cells that were proliferated in either the presence or the absence of B27 supplement, the cells proliferated in the presence of B27 expressed higher levels of endodermal markers than cells proliferated in the absence of B27. This data demonstrates that the skin-derived MSCs of the invention can differentiate to cell types derived from all three germ layers.

Additionally, these experiments demonstrate that the modulating of multiple plating conditions (in this case the addition of both B27 supplement and nicotinamide), at different times, can effect the differentiation of the skin-derived MSCs.

Skin-derived MSCs can differentiate to cell types of both neural and non-neural lineages. We demonstrate that the MSCs can give rise to several different non-neuronal cell types including smooth muscle cells, adipocytes, cartilage, bone, skeletal muscle, and cardiac muscle. Additionally, we show that the skin-derived MSCs can express transcripts consistent with endoderm differentiation. The tremendous differentiative potential of skin-derived MSCs suggests that in addition to the many cell types shown here, MSCs can also give rise to other mesodermal and endodermal cell types. Furthermore, these results demonstrate that changes in plating conditions (i.e., alterations in serum concentrations, the addition of pharmacological agents and small molecules, and/or co-culturing cells with other cell types) can have dramatic effects on cell proliferation, differentiation and/or survival.

Example 16: Contacting MSCs with agents to influence differentiation

As described in detail above, the proliferation, differentiation, or survival of the cells of the invention can be influenced by modulating the culture conditions. For example, we have shown that changes in the plating conditions, or the addition of pharmacological agents to the culture medium influences the proliferation, differentiation and/or survival of MSCs.

We show that the proliferation, differentiation or survival of MSCs can also be influenced by contacting the cells with a therapeutic protein including one or more cytokine, growth factor, extracellular protein, etc. One of skill will recognize that the concentration of these agents can be altered to determine the optimal dose.

5 Additionally, the therapeutic proteins may be added alone, or in combination, and combinations of proteins may be administered simultaneously or at varying timepoints.

Skin derived MSCs were obtained and cultured as described in detail above. To induce differentiation, cells were plated in the presence of 5 % serum
10 supplemented with either retinoic acid or BMP-7. Neuronal differentiation was analyzed using a polyclonal anti-neurofilament antibody. Addition of either retinoic acid or BMP-7 enhances the number and complexity of neurofilament positive cells, in comparison to cells differentiated in the presence of serum alone (Fig. 21).

15 Example 17: Skin-derived MSCs are a distinct population of stem cells

We have demonstrated that the skin-derived multipotent stem cells of the invention can differentiate to produce both neural and non-neural cell types. Furthermore, we have demonstrated that these skin-derived stem cells can produce at least six mesodermal cell types (smooth muscle, adipocyte, cartilage, bone,
20 skeletal muscle, and cardiac muscle). The ability of the stem cells of the invention to differentiate along mesodermal lineages is a characteristic of mesenchymal stem cells previously isolated from sources including bone marrow.

Although previous experiments using mesenchymal stem cells indicate that such cells are selectively adherent (in contrast to the skin-derived cells of the invention), we performed morphological and immunocytochemical analysis to
25 demonstrate that the skin-derived cells of the invention are distinct from the mesenchymal stem cells previously identified. Bone marrow derived mesenchymal stem cells were obtained from BioWhittaker, and were cultured under the conditions described herein for skin-derived stem cells.

30 When grown under identical conditions, the two cell populations have significantly different morphology and growth characteristics. The mesenchymal stem cells do not proliferate in suspension when cultured under conditions which

allow the skin-derived stem cells to grow as non-adherent clusters as described in detail herein. The cells were dissociated and plated overnight under the conditions described for the skin-derived cells. The two cell types are morphologically distinct: the skin-derived cells are considerably smaller while the mesenchymal stem cells have a more flattened appearance. Additionally although mesenchymal stem cells rapidly proliferate in standard mesenchymal cell medium, they survive but do not readily proliferate under the conditions used here.

Immunocytochemical analysis further illustrates the differences between these two cell types. Cells were dissociated, plated overnight, and analyzed immunocytochemically for the expression of nestin and fibronectin. Both mesenchymal stem cells and the skin-derived multipotent stem cells of the invention express fibronectin. However, the two cell types differed in the expression of nestin. Skin-derived stem cells express nestin whereas mesenchymal stem cells do not (Fig. 22).

Despite the ability of skin-derived stem cells to differentiate along several mesodermal lineages, the stem cells of the invention are distinct from previously identified mesenchymal stem cells. These differences are demonstrated by the differential morphology and protein expression observed when mesenchymal stem cells are cultured under the conditions described herein for the proliferation and differentiation of skin-derived stem cells.

Example 18: Isolation of Skin-derived Multipotent Stem Cells from Human Foreskin

We have previously demonstrated that the multipotent stem cells of the invention can be isolated from both rodent and human skin. Exemplary samples have been obtained from the scalp, back, and abdomen of donors. One of the unique advantages of the present invention is that skin represents a plentiful and easily accessible source of autologous or heterologous stem cells for transplantation.

However, in addition to autologous or heterologous skin samples taken specifically to generate stem cells for transplantation, skin samples are routinely harvested from healthy donors in the course of many medical procedures. Such samples represent a plentiful source of tissue for the generation of skin-derived stem

cells. Such stem cells, or the differentiated progeny thereof, could be used for research purposes, as well as for autologous or heterologous transplantation. Exemplary procedures which generate excess skin include circumcision and cosmetic surgery (e.g., face lifts, liposuction, and “tummy tucks”). Typically, the
5 excess tissue generated following these procedures is removed and discarded from otherwise healthy patients.

In one embodiment, stem cells can be isolated and cultured from said excess tissue. Such stem cells, or the differentiated progeny thereof, can be used immediately for transplantation or research purposes. Alternatively, the stem cells,
10 or the differentiated progeny thereof, can be banked for later use by the donor (autologous transplantation), or for the treatment of a related or unrelated recipient.

In another embodiment of the present invention, stem cells are harvested from the foreskin of a male patient. The stem cells, or the differentiated progeny thereof, can be stored for later use by either the same male patient or his blood
15 relatives. Alternatively, the stem cells, or the differentiated progeny thereof, can be used for the treatment of an unrelated recipient.

Foreskin samples from human patients were obtained from surgeons performing circumcisions. The samples were taken from males ranging in age from
20 newborns to adolescents. We note that we have generated proliferating cultures of non-adherent skin-derived stem cells from 21 samples, and have not observed any significant differences in the survival, proliferation, or differentiation characteristics among the cultures based on the age of the donor.

The quantity of tissue obtained following circumcision is relatively
25 small. Accordingly, we reasoned that the number of stem cells in said tissue may be relatively low, and that the survival of cultures derived from these samples may improve if the stem cells could be enriched in relation to non-stem cells in the sample. Previous studies demonstrated that skin-derived stem cells reside in the dermal layer of the skin. Thus, we employed a novel method for isolating and
30 culturing stem cells from limiting quantities of tissue. Briefly, foreskin samples were first cut into pieces and then enzymatically digested to separate the dermal and epidermal layers. Specifically, we digested the tissue for 24-48 hours at 4 °C in an

enzyme blend containing collagenase and either Dispase or thermolysin. However, one of skill in the art can readily select from among commercially available proteases to choose one or more enzymes which would achieve a similar effect. Following separation of the dermal and epidermal layer, the dermal layer was
5 dissociated by further digestion in the enzyme blend for 30 minutes at 37 °C followed by trituration to release single cells.

We cultured the cell suspension, as previously described, in non-adherent vessels in the presence of EGF and FGF2. Figure 23 demonstrates that skin-derived stem cells harvested from human foreskin proliferate as non-adherent clusters. The
10 clusters are morphologically indistinguishable from skin-derived stem cells derived from rodent tissue. Skin-derived clusters are loosely compacted, and the cells can be readily dissociated manually without the use of proteases. Such characteristics appear to distinguish skin-derived clusters from CNS-derived neurospheres. Note that we have cultured these proliferating skin-derived stem cells in the presence and
15 absence of LIF, and have observed no significant differences in their proliferation, differentiation or survival characteristics. Furthermore, we have currently passaged and maintained foreskin derived stem cells as proliferating cultures for greater than three months.

One of the characteristics of skin-derived stem cells isolated from rodents
20 or other human tissue is the differentiation capacity of these cells. We have previously demonstrated that skin-derived stem cells can differentiate along a range of neuronal and non-neuronal fates. Similarly, foreskin-derived stem cells can differentiate along a wide range of neuronal and non-neuronal fates.

The expression of various neural and non-neural markers was assayed
25 following differentiation of foreskin-derived stem cells. Briefly, proliferating, non-adherent clusters were dissociated and plated on an adherent substratum in the presence of proliferation medium. After several days, the medium was changed to differentiation medium (5% fetal bovine serum / no mitogens), and marker expression was analyzed during this differentiation phase. Our results indicate that
30 foreskin derived stem cells can differentiate along a wide range of neuronal and non-neuronal cell types. These results are consistent with our finding for the differentiation potential of skin-derived stem cells obtained from rodents and other

human tissue samples. For example, under differentiation conditions, foreskin derived stem cells can express nestin, fibronectin, bIII-tubulin, neurofilament-M, GFAP, CNP, S100, peripherin, and smooth muscle actin (Figures 23-27). The expression of bIII-tubulin and neurofilament-M, in combination with the morphology of these cells, is indicative of the formation of highly complex neurons (Figure 24). The expression of GFAP and CNP demonstrate the ability to give rise to glial cell types (Figure 25). The expression of S100 and peripherin indicates that foreskin-derived stem cells can generate additional neuronal cell types including bipolar cells (S100) and peripheral neurons (peripherin) (Figure 26). Finally, the expression of the non-neural marker smooth muscle actin (Figure 27) indicates that, as has been observed for other skin-derived stem cells, foreskin-derived stem cells have extensive differentiation capacity and can give rise to both neural and non-neural cell types.

Example 19: The Multipotent Stem Cells of the Invention are Distinct from Neurospheres

We have previously observed that the stem cells of the present invention are distinguishable from CNS derived Neurospheres based on several criteria. Proliferating cultures of the stem cells of the present invention, derived from skin, tongue, or olfactory epithelium, are morphologically different from CNS derived Neurospheres. Proliferating cultures of the multipotent cells of the present invention are more loosely compacted, and appear as “grape-like” clusters. In comparison, CNS Neurospheres proliferate as a tight ball.

In addition to these morphological differences in appearance, we compared the expression of several markers to assess potential differences in protein expression between proliferating cultures of the stem cells of the present invention and CNS derived Neurospheres. Figure 28 shows the results of immunocytochemistry to assess the expression of nestin and fibronectin protein in proliferating cultures of rat neurospheres and in proliferating cultures of the multipotent stem cells of the present invention. The top panels shows that proliferating cultures of Neurospheres express nestin protein, but do not express fibronectin protein. In contrast, the middle and bottom panels show that

proliferating cultures of the multipotent stem cells of the present invention express both nestin and fibronectin protein. We note that multipotent stems derived from either olfactory epithelium or skin express both nestin and fibronectin protein.

Additionally we examined, by RT-PCR, the expression of two
5 transcription factors which are highly expressed in proliferating cultures of the skin derived multipotent stem cells of the present invention. Dermo-1 is an embryonic dermis-specific basic helix-loop-helix transcription factor and SHOX2 is expressed in embryonic craniofacial derivatives.

Briefly, skin-derived multipotent stem cells and CNS Neurospheres were
10 cultured under standard proliferation conditions, and RNA was harvested from proliferating clusters for RT-PCR analysis using primers for Dermo-1 and SHOX2. In all PCR reactions, primers which amplify GAPDH were included as a control. Figure 29 demonstrates that despite robust expression of Dermo-1 and SHOX2 in skin-derived multipotent stem cells (SKPs), little or no expression of these genes is
15 observed in Neurosphere cultures (Neuro).

We also note that despite extensive similarities in morphology, marker expression, and differentiation potential between multipotent stem cells derived from olfactory epithelium and multipotent stem cells derived from skin, we also note a difference between the two stem cell populations. Figure 42 shows the results of
20 cell counting experiments where the number of cells expressing p75 protein (when assayed by immunocytochemistry) were counted in proliferating cultures of olfactory epithelium derived stem cells and in proliferating cultures of skin derived stem cells. The left hand column is a negative control for proliferating cultures of skin derived stem cells. Note that the background level of p75 expression in the
25 negative control is approximately 1%. The middle column presents the results of cell counting of p75 positive cells in proliferating cultures of skin derived stem cells. The right column presents the results of cell counting of p75 positive cells in proliferating cultures of olfactory epithelium derived stem cells. Note that greater than 32% of cells in proliferating cultures of olfactory epithelium derived stem cells
30 are positive for p75 protein. In contrast, proliferating cultures of skin derived stem cells are essentially negative for p75 with less than 3% of the cells expressing p75 protein. These results indicate that despite extensive similarities between olfactory

epithelium derived stem cells and skin derived stem cells, there are also specific differences between these populations of stem cells.

Example 20: Method of “Neuralizing” Multipotent Stem Cells

5 We have demonstrated that the stem cells of the present invention are capable of differentiating to give rise to both neural and non-neural cell types. We have further demonstrated that the differentiation of the stem cells of the present invention can be influenced by modulating the plating conditions. We now demonstrate that the differentiation of the stem cells of the present invention can be
10 further biased using a multi-step neuralization method. This multi-step process comprises a proliferation phase, a pre-differentiation phase, and a differentiation phase, and biases cells to a neural fate.

 The general protocol for neuralizing stem cells involves three steps. In the first step (the proliferation phase), stem cells are cultured as non-adherent,
15 proliferating cultures under standard proliferation conditions. In the second step (the pre-differentiation phase), proliferating spheres are plated on laminin or another adherent matrix and cultured for several days (typically 3 days). Although the spheres are plated during this pre-differentiation phase, they are still cultured under proliferation culture conditions. Finally, in the differentiation phase, the mitogens
20 present in the media under proliferation conditions (EGF, FGF) are removed, and exogenous factors are added to the media to influence differentiation. These factors include serum, retinoic acid, therapeutic proteins, etc. During this differentiation phase, any plating condition can be altered to influence differentiation, as outlined in detail throughout the application. The distinguishing feature of this neuralization
25 protocol is the pre-differentiation phase. Without wishing to be bound by any particular theory, it is following this phase that the cells are neuralized, and thus more able to respond to differentiation conditions by differentiating along a neuronal pathway. The general method for biasing the stem cells of the invention to a neural fate is summarized schematically in Figure 30.

30 Using this method of biasing cells to a neural fate (“neuralizing cells”), we observed increased differentiation to a neuronal phenotype. This differentiation can be further improved or influenced by modulating the plating conditions (e.g.,

addition of one or more factors such as serum, small molecules, and therapeutic proteins) during either the pre-differentiation or differentiation phases.

a. LIF

5 Figure 31 and 32 demonstrate that the addition of LIF during the differentiation phase increases neuronal differentiation in neuralized cultures. We note that we have previously shown that the multipotent stem cells of the present invention do not require LIF to proliferate. In fact, this is one of many characteristics that distinguish these cells from Neurospheres. Although the cells of the present invention do not require
10 LIF to proliferate, we now demonstrate that LIF acts not as a proliferation or survival factor, but rather as a differentiation factor. Proliferating cultures of skin-derived stem cells were cultured under pre-differentiation conditions for 3 days, and then subjected to differentiation conditions for 7 days in either serum free media alone or in serum free
15 media supplemented with LIF. Figure 31 demonstrates increased neurogenic differentiation in cells differentiated in the presence of LIF as assessed by increased expression of nestin and β III tubulin.

Figure 32 provides additional evidence that LIF increases neuronal differentiation. Proliferating cultures of skin derived stem cells
20 were pre-differentiated for 3 days, and differentiated for 7 days in 10% serum plus LIF. These conditions similarly resulted in increased neurogenesis.

b. Sonic hedgehog

25 Figure 33 demonstrates that contacting the cells with Sonic hedgehog, either during the pre-differentiation phase or the differentiation phase, promotes neurogenesis. Cells depicted in the top panels are double labeled with nestin and Hoechst and cells depicted in the bottom panels are labeled with tyrosine hydroxylase (TH).
30 Proliferating cultures of skin derived stem cells were pre-differentiated for 3 days, in the presence or absence of Sonic hedgehog, and cultured under differentiation conditions for 7 days in 1% serum in the presence

or absence of Sonic hedgehog. These experiments demonstrate that Sonic hedgehog promotes differentiation of skin derived stem cells to a neural fate.

5 *c. Types of Neurons Generated*

We previously demonstrated that skin-derived stem cells can differentiate to a neuronal fate. We now provide a method of biasing the differentiation of the stem cells to a neuronal fate (i.e., a method of “neuralizing” the cells). We note that we have observed a wide range of neuronal cell types differentiated using this method. Figures 34 and 35 present examples of the diverse range of neuronal cell types differentiated from skin derived stem cells using this neuralizing method to bias the fate of the cells.

Proliferating cultures of skin derived stem cells were pre-differentiated for 3 days, and cultured for 7 days under differentiation conditions in the presence of serum. Figure 34 shows neurons expressing D β H, peripherin, nestin, and tyrosine hydroxylase. D β H is a marker of noradrenergic and adrenergic neurons. Peripherin is a marker of peripheral nervous system neurons. TH is a marker of dopaminergic neurons, and is also expressed in noradrenergic and adrenergic neurons. Figure 35 shows neurons expressing MAP2 which is a marker of autonomic neurons and central nervous system neurons. Figures 34 and 35 demonstrate the diverse range of neuronal cell types that can be generated using the neutralization method and standard differentiation conditions. By modulating plating conditions during the pre-differentiation and/or the differentiation phases, the fate of the neurons generated in these cultures can be further influenced.

30 *d. Schwann Cell Differentiation*

We also examined whether the neuralization protocol outlined in detail above influenced differentiation of the multipotent stem cells of the invention to Schwann cells. Proliferating cultures of skin derived stem

cells were pre-differentiated for 3 days, and then cultured under differentiation conditions for 8 to 10 days. During the differentiation period the cells were contacted with one or more agents that have been shown to affect the differentiation of Schwann cell progenitor cells to a Schwann cell fate. Differentiated cells were then analyzed based on both morphology, and on expression of one or more Schwann cell markers including S100, MBP and PM22.

Figure 36 demonstrates the results of one differentiation scheme used to generate cells with morphology and gene expression indicative of Schwann cells. Proliferating cultures of skin derived stem cells were pre-differentiated for 3 days, and then subjected to a two step differentiation process. In the first phase, the cells were cultured under differentiation conditions in the presence of 10% serum for 5 days, and subsequently contacted with forskolin for 3 days. Figure 36 demonstrates that these cells express S100, MBP, and PMP22, and additionally adopt a morphology consistent with Schwann cells.

Figure 37 further supports that skin derived stem cells differentiate to Schwann cells. Proliferating cultures of skin derived stem cells were pre-differentiated for 3 days, and then cultured under differentiation conditions for 10 days in standard N2 media in the presence or absence of forskolin. Note the complex Schwann cell morphology observed in cultures differentiated in the presence of forskolin (compare the right panel (+ forskolin) with the left panel (- forskolin)).

Figure 38 demonstrates that Heregulin β promotes Schwann cell differentiation. Proliferating cultures of skin-derived stem cells were pre-differentiated for 3 days, and then cultured under differentiation conditions for 10 days in media supplemented with forskolin in the presence or absence of Heregulin β . Note the increased Schwann cell differentiation and morphology observed in the culture differentiated in the presence of Heregulin β (compare the right panel (+Heregulin β) to the left pane (- Heregulin β))

Figure 39 demonstrates that plating density can further influence Schwann cell differentiation. Proliferating cultures of skin derived stem cells were pre-differentiated for 3 days, and then cultured under differentiation conditions for 10 days in the presence or absence of forskolin. The cells were plated at various densities using 5 fold serial dilutions. The images presented in Figure 39 show cells plated at high density (left panel) and low density (right panel), and differentiated in the presence of forskolin. Note the vastly improved Schwann cell differentiation observed in the low density culture in comparison to the high density culture.

The results presented in Figures 36-39 demonstrate that skin derived stem cells readily differentiate to Schwann cells, and that many plating conditions can be modulated to further influence Schwann cell differentiation. Many of the conditions examined are summarized in Figure 40. In this chart, Schwann cell differentiation under a variety of conditions is compared between cells cultured at high density (HighD) and cells cultured at low density (LowD). The number of "+" depicts the relative degree of Schwann cell differentiation observed under the given conditions. N2 represents cells differentiated in standard differentiation media, S represents cells differentiated in standard differentiation media plus serum, F represents cells differentiated in standard differentiation media plus forskolin, S+F represents cells differentiated in standard differentiation media plus both serum and forskolin, S+F+H β represents cells differentiated in standard differentiation media plus serum, forskolin, and heregulin β , and F+H β represents cells differentiated in standard differentiation media plus forskolin and heregulin β .

Example 21: Hippocampal Slice Culture

One of the primary goals of stem cell research is to treat human disorders and injuries which result from cell and tissue damage and loss. Neurodegenerative diseases currently exact an enormous financial and emotional toll, and improved methods of treatment for the wide range of neurodegenerative diseases would

represent a tremendous medical advance. The multipotent stem cells of the present invention can differentiate to a wide range of neuronal cell types, and the neuronal differentiation of these stem cells can be influenced by the methods discussed in detail herein. Accordingly, the stem cells of the present invention represent a
5 potential source of cells for the treatment of a wide range of neurodegenerative diseases.

To further demonstrate that the multipotent stem cells of the invention can differentiate *in vivo*, and integrate into the complex cytoarchitecture of endogenous neural tissue, we have developed an organotypic hippocampal slice
10 culture system. This model can be used to ask whether the stem cells of the present invention can differentiate into neurons and integrate into the cytoarchitecture of the brain slice following transplantation. The hippocampal slice culture has several advantages. Most notably, it retains the cytoarchitecture of the mature
15 hippocampus, while still being easily accessible and amenable to routine observation and microscopic analysis. This system can be used to examine the effects of transplanting multipotent stem cells, neuralized multipotent stem cells, or cells differentiated from either multipotent stem cells or neuralized multipotent stem cells.

Figure 41 summarizes the culture system. Briefly, the hippocampus is dissected from P7-P9 rats pups. These slices are placed in wells which float on a
20 semiporous membrane. The slices are maintained at 37 °C/5% CO₂, and media is applied via a compartment beneath the slices. Approximately 5-7 days after dissection, the slices are ready for further experimentation.

Prior to transplantation, proliferating cultures of mouse skin derived stem cells are cultured under proliferation conditions, and subjected to pre-differentiation.
25 Cells are plated and pre-differentiated for 6 days in the presence of either (a) media plus 20% serum, (b) media plus 20% serum plus FGF, or (c) media plus retinoic acid. Following 6 days in culture under pre-differentiation conditions, neuralized mouse skin-derived stem cells are transplanted to rat hippocampal slice cultures. By transplanting mouse cells to rat slices, donor cells can be more readily distinguished
30 from endogenous cells. Following transplantation, the transplanted cells are observed to determine their differentiation and integration into the hippocampal slice tissue.

The hippocampal slice culture system described here provides an excellent model system in which to examine the in vivo neuronal differentiation and/or integration of multipotent stem cells. Proliferating stem cells, neuralized stem cells, or differentiated neuronal tissue can be transplanted to the hippocampal slices and the effects of such transplants can be further analyzed.

The foregoing experiments were performed using the following methods, except where otherwise noted.

Skin-derived MSC culture

For neonatal (three to 14 days) and adult (two months to one year) mice, skin from abdomen and back was carefully dissected free of other tissue, cut into 2-3 mm³ pieces, washed three times in HBSS, and then digested with 0.1% trypsin for 40 minutes at 37 C, followed by 0.1% DNAase for one minute at room temperature. Tissue pieces were then washed twice with HBSS, once with media (DMEM-F12, 3:1, 1 g/ml fungizone, 1% penicillin/streptomycin) containing 10% rat serum (Harlan Bioproducts), and twice with serum-free media. Skin pieces were then mechanically dissociated in media, and the suspension poured through a 40 M cell strainer (Falcon). Dissociated cells were centrifuged, and resuspended in 10 ml media containing B-27 supplement, 20 ng/ml EGF and 40 ng/ml bFGF (both Collaborative Research). Cells were cultured in 25 cm² tissue culture flasks (Corning) in a 37 C, 5% CO₂ tissue culture incubator.

To culture human skin-derived MSCs, two to three pieces of scalp tissue ranging between 4-9 mm² (generated by placement of the stereotaxic apparatus for neurosurgery) were washed with HBSS, any subcutaneous tissue was removed, and the skin was cut into small pieces 1-2 mm³ in size. Tissue pieces were transferred to 15 mL Falcon tubes, washed three times with HBSS, and enzymatically digested in 0.1% trypsin for 40 minutes at 37 C, and then washed as for mouse tissue. Dissociated cells were suspended in 5 mL of the same media used for mouse cultures, with the addition of 20 ng/ml LIF (R&D Systems Inc.). However, we note that further experiments indicated that LIF is not necessary for the survival and proliferation of skin derived stem cells. The cell suspension was placed in Falcon 6-well tissue culture plates and maintained in a 37 C, 5% CO₂ tissue culture incubator.

Cells were subcultured by partial dissociation of the clusters that formed every 7 to 10 days.

To passage floating clusters of cells, the medium containing the cell clusters was centrifuged, the cell pellet mechanically dissociated with a fire-polished
5 Pasteur pipette, and the cells reseeded in fresh media containing B-27 supplement and growth factors as above. Cells were passaged every 6 to 7 days. For induction of differentiation into smooth muscle cells, the cell clusters were centrifuged, the growth factor-containing supernatant removed, and the clusters resuspended in fresh media containing B-27 supplement and either 3% rat serum or 1-3% fetal bovine
10 serum. The clusters were then plated onto 4-well Nunclon culture dishes coated with poly-D-lysine/laminin, and the medium was changed every 3 to 7 days.

Transplantation of olfactory epithelium-derived MSCs

Olfactory epithelium-derived MSCs were purified and cultured as
15 described herein. Female Sprague-Dawley rats or CD1 albino mice (Charles River, Montreal, Quebec, Canada) weighing 180-200 g or 25-30 g, respectively, were anaesthetized with a mixture of ketamine (90 mg/kg) and xylazine (10 mg/kg) (intraperitoneal) prior to stereotactic injections of 24 µg of 6-hydroxydopamine hydrobromide (dissolved in 5 µL of 0.9% saline containing 0.2 mg/ml ascorbate)
20 into the right medial forebrain bundle (Tooth bar:-2.4 mm; A:-4.4 mm; L:1.0 mm; V:7.5 mm). Two weeks after the lesion, animals were tested for rotational behavior. Animals were immunosuppressed with cyclosporine (40 mg/kg, intraperitoneal) once a day until the day of sacrifice. For MSC transplantation, anaesthetized animals were mounted in a Kopf stereotactic apparatus, and 2 x 2.5 µL aliquots of
25 MSCs were injected unilaterally into the lesioned caudate putamen or bilaterally in some animals. The injections were made using a 5 µL Hamilton syringe at the following coordinates: Tooth bar, -2.4 mm; A: 0.2; L: 3.0; V: 5.5-6.0. Injections were performed over a period of three minutes, a further five minutes was allowed for diffusion, and the needle was then retracted. These 5 µL injections contained
30 MSCs derived from one neonatal pup cultured for 7 to 14 days. For the BrdU experiments, BrdU (10 µM) was added to culture media for 18 hours, after which

the MSCs were washed three times with fresh media to remove the BrdU, and then transplanted one day later.

Transplantation of skin-derived MSCs

5 Labeling of skin-derived MSCs was performed as follows. Three days prior to transplantation, free-floating cell clusters were partially dissociated by gentle trituration, and then exposed to 50 MOI of a recombinant adenovirus expressing GFP, using standard techniques. Twenty-four hours later, the MSCs were centrifuged, washed, and resuspended in fresh medium containing 2 μ M BrdU
10 for an additional two days. Prior to transplantation, MSCs were rinsed five times with fresh medium and resuspended to a concentration of 50,000 cells/ μ l. At the time of transplantation, approximately 75% of the MSCs expressed GFP, while 95% were BrdU positive.

 MSCs labeled with BrdU and GFP were stereotactically injected into the
15 right lateral ventricle of cryoanaesthetized two day old rat pups (co-ordinates from Bregma: lateral 1.5 mm, ventral 3.3 mm). Approximately 50,000 cells were injected over a three minute period in a volume of 1 μ L. Fourteen days following transplantation, mice were perfused with 50 mL 4% formaldehyde buffered with PBS. Fifty micron coronal sections through the forebrain were cut using a freezing
20 microtome and analyzed immunocytochemically. All eight animals receiving cell transplants showed extensive labeling for tagged cells. No evidence of tumor formation was observed.

Immunostaining

25 Immunostaining of olfactory epithelium-derived MSCs was performed as follows. With the exception of GC immunocytochemistry, culture dishes were washed twice with Tris-buffered saline (TBS; 10mM Tris, 150mM NaCl, pH 8), then fixed with 4% formaldehyde, washed three times with TBS, blocked with TBS plus 2% goat serum (Jackson ImmunoResearch, Mississauga, Ontario, Canada),
30 and 0.1% Triton-X (Sigma Chemicals, St. Louis MO) for 30 minutes, then incubated with primary antibody in TBS plus 2% goat serum. Following primary antibody incubation, the dishes were washed three times with TBS, incubated in secondary

antibody in TBS plus 2% goat serum, washed three times, and then viewed with a fluorescence inverted microscope. The antibodies to GFAP (Boehringer Mannheim, Laval, Quebec, Canada), β III tubulin (Sigma), NeuN (Dr. R. Mullen), MAP-2 (clone AP-20; Sigma), and NF-160 (American Tissue Culture Collection, Manassas VA) were monoclonal antibodies used at concentrations of 1:200; 1:25; 1:10, and 1:1 respectively. Antibodies to nestin (a gift from Dr. Ron MacKay (National Institutes of Health), TH (Eugenetech Eugene, OR), and DBH (Eugenetech) were rabbit polyclonal antibodies used at concentrations of 1:1000, 1:200, and 1:200 respectively. Secondary antibodies Cy3 conjugated goat anti-mouse (Jackson ImmunoResearch) and Cy3 conjugated goat anti-rabbit (Jackson ImmunoResearch), and were used at 1:1500. For double-labelling experiments, we used FITC goat anti-mouse (Jackson ImmunoResearch).

For GC immunocytochemistry, living cultures were incubated in DMEM containing HEPES, 5% heat inactivated horse serum (HS), and 1:10 GC antibody for 30 min at 37 C, washed three times with the medium/HEPES/HS, fixed with 4% formaldehyde for 15 minutes, rinsed three times in TBS, incubated in Cy3 conjugated goat anti-mouse antibody (1:1500) for two hours, and finally washed three times in TBS. Cultures processed for immunocytochemistry without primary antibodies revealed no staining.

Immunocytochemical analysis of cultured skin-derived MSCs was performed as follows. The primary antibodies that were used were: anti-nestin polyclonal (1:250, Dr. Ron McKay, NINDS), anti-nestin monoclonal (1:400, PharMingen Inc.), anti- β III-tubulin monoclonal (1:500, Tuj1 clone, BabCo), anti-neurofilament-M polyclonal (1:200, Chemicon Intl.), anti-GAD polyclonal (1:800, Chemicon Intl.), anti-NSE polyclonal (1:2000, Polysciences Inc.), anti-GFAP polyclonal (1:200, DAKO), anti-CNPase monoclonal (1:400, Promega), anti-p75NTR polyclonal (1:500, Promega), anti-SMA monoclonal (1:400, Sigma-Aldrich), and anti-A2B5 monoclonal (Dr. Jack Snipes, M.N.I.). The secondary antibodies were Cy3-conjugated goat anti-mouse (1:200), Cy3-conjugated goat anti-rabbit (1:400), FITC-conjugated goat anti-mouse (1:50-1:100), and FITC-conjugated goat anti-rabbit (1:200) (all from Jackson Immunoresearch Laboratories).

Immunocytochemical analysis of free-floating brain sections was performed by DAB immunohistochemistry. For GFP, sections were incubated in 0.3% H₂O₂ for one hour to inhibit endogenous tissue peroxidase activity prior to blocking. For BrdU immunohistochemistry, sections were pre-incubated in 0.5% sodium borohydride for 20 minutes prior to blocking of endogenous peroxidase activity in 0.03% H₂O₂ for 30 minutes. To permeabilize the nuclei for BrdU immunohistochemistry, sections were incubated in 1% DMSO for 10 minutes, the DNA denatured with 2N HCl for 60 minutes, and the HCl neutralized with 0.1M borate buffer for 5 minutes. All sections were blocked for one hour in 10% BSA, and then incubated for 48 hours at 4°C with either anti-GFP (1:1000, Clontech) or anti-BrdU (1:100, Becton-Dickinson). Primary antibodies were detected using a biotinylated horse anti-mouse secondary antibody (1:200, Vector Laboratories) for one hour at room temperature, and visualized using the Vectastain kit (Vector Laboratories) and a nickel-enhanced DAB reaction containing 0.05% DAB, 0.04% nickel chloride, and 0.015% H₂O₂. Sections were mounted onto slides, dehydrated through a series of ethanols and Histoclear (Fisher Scientific), and coverslipped using Permount (Fisher Scientific).

Fluorescence immunohistochemistry was performed to co-localize GFP expression with NSE. Free-floating sections were blocked in 10% BSA for one hour at room temperature, and then incubated 48 hours at 4°C in a solution containing mouse anti-GFP and rabbit anti-NSE. Sections were incubated with Cy3 conjugated anti-mouse and FITC conjugated anti-rabbit secondary antibodies for one hour at room temperature, and coverslipped using Sigma Mounting Medium.

25

Other Embodiments

The present invention has been described in terms of particular embodiments found or proposed by the present inventors to comprise preferred modes for the practice of the invention. It will be appreciated by those of skill in the art that, in light of the present disclosure, numerous modifications and changes can be made in the particular embodiments exemplified without departing from the

30

intended scope of the invention. All such modifications are intended to be included within the scope of the appended claims.

All publications, patents and patent applications are herein incorporated by reference in their entirety to the same extent as if each individual publication,
5 patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety.

Claims:

1. A method of treating a patient with cell damage or disease comprising
transplanting multipotent mammalian stem cells, wherein said stem cells (i)
5 form non-adherent clusters in culture; (ii) are self-renewing; (iii) are positive
for nestin and fibronectin protein; and (iv) can differentiate into both
neuronal and non-neuronal cell types.
2. A method of treating a patient with cell damage or disease comprising
10 transplanting multipotent mammalian stem cells, wherein said stem cells (i)
form non-adherent clusters in culture; (ii) are self-renewing; (iii) are positive
for nestin and fibronectin protein; (iv) are negative for p75 protein; and (v)
can differentiate into both neuronal and non-neuronal cell types.
- 15 3. The method of claim 1 or 2, wherein said stem cells are isolated from
peripheral tissue.
4. The method of claim 3, wherein said peripheral tissue does not include
olfactory epithelium.
- 20 5. The method of claim 3, wherein said peripheral tissue is skin.
6. The method of any of claims 1-5, wherein the multipotent stem cells are
autologously derived.
- 25 7. The method of any of claims 1-5, wherein the multipotent stem cells are
derived from a genetically related donor.
8. The method of any of claims 1-5, wherein the multipotent stem cells are
30 derived from a genetically unrelated donor.

9. The method of any of claims 1-5, wherein the cell damage or disease is selected from a neurodegenerative disease, diabetes, cardiovascular disease, heart attack, arthritis, or stroke.
- 5 10. The method of any of claims 1-5, wherein the cell damage or disease is the result of bacterial or viral infection.
11. The method of any of claims 1-5, wherein the cell damage or disease is the result of traumatic injury including fractures, lacerations, and burns.
- 10 12. The method of any of claims 1-5, wherein the multipotent stem cells are transplanted at the site of cell damage or disease.
13. The method of any of claims 1-5, wherein the multipotent stem cells are delivered to the site of cell damage via the bloodstream.
- 15 14. The method of any of claims 1-5, wherein the patient is a human patient.
15. A method of differentiating a multipotent stem cell, comprising
- 20 (i) providing a cellular composition comprising a purified population of multipotent mammalian stem cells, which stem cells form non-adherent clusters in culture, are self-renewing, are positive for nestin and fibronectin protein, and can differentiate into both neuronal and non-neuronal cell types;
- 25 (ii) plating said non-adherent clusters; and
- (iii) modulating the plating conditions,
- wherein following steps (ii) and (iii) the multipotent stem cells differentiate to one or more neuronal or non-neuronal cell types.
- 30 16. A method of differentiating a multipotent stem cell, comprising
- (i) providing a cellular composition comprising a purified population of multipotent mammalian stem cells, which stem cells form non-

adherent clusters in culture, are self-renewing, are positive for nestin and fibronectin protein, are negative for p75 protein, and can differentiate into both neuronal and non-neuronal cell types;

(ii) plating said non-adherent clusters; and

5 (iii) modulating the plating conditions,

wherein following steps (ii) and (iii) the multipotent stem cells differentiate into one or more neuronal or non-neuronal cell types.

17. The method of claim 15 or 16, wherein said multipotent mammalian stem
10 cells are isolated from peripheral tissue.

18. The method of claim 17, wherein said peripheral tissue does not include olfactory epithelium.

15 19. The method of claim 17, wherein said peripheral tissue is skin.

20. The method of any of claims 15-19, wherein said differentiated cell types are selected from the group consisting of epithelial cells, endothelial cells, skeletal muscle cells, cardiac muscle cells, connective tissue cells, lung cells, adipocytes,
20 islet cells, hematopoietic cells, chondrocytes, bone, kidney cells, and hepatocytes.

21. The method of any of claims 15-19, wherein said differentiated cell types are selected from the group consisting of astrocytes, oligodendrocytes, and neurons.

25 22. The method of claim 21, wherein said differentiated cells express one or more markers selected from the group consisting of GFAP, neurofilament 160, β III tubulin, NeuN, neurofilament-M (NFM), neuron-specific enolase, galactocerebroside, GAD, tyrosine hydroxylase (TH), dopamine β -dehydrogenase and CNPase.

30

23. A method for preparing stem cell preparations, comprising:

(a) obtaining an epithelial tissue sample;

- (b) culturing cells dissociated from said tissue sample;
 - (c) isolating from the culture multipotent cells characterized by the following: form
 - non-adherent clusters in culture; are self renewing; express nestin and fibronectin; and differentiate into ectodermal and mesodermal cell types.
24. A method for preparing stem cell preparations, comprising:
- (a) obtaining an epithelial tissue sample;
 - (b) separating the dermal and epidermal layers of said tissue sample;
 - (c) culturing cells dissociated from the dermal layer of said tissue sample;
 - (d) isolating from the culture multipotent cells characterized by the following: form
 - non-adherent clusters in culture; are self renewing; and differentiate into ectodermal and mesodermal cell types.
25. A method for preparing stem cell preparations, comprising:
- (a) obtaining an epithelial tissue sample from a patient;
 - (b) culturing cells dissociated from said tissue sample;
 - (c) isolating from the culture multipotent cells characterized by the following: form non-adherent clusters in culture; are self renewing; express nestin and fibronectin; and differentiate into ectodermal and mesodermal cell types; and
 - (d) preserving and storing the multipotent cells for later retrieval.
26. A method for preparing cell preparations, comprising:
- (a) obtaining an epithelial tissue sample from a patient;
 - (b) culturing cells dissociated from said tissue sample under conditions wherein multipotent cells are expanded, which multipotent cells are characterized by the following: form non-adherent clusters in culture;

- are self renewing; express nestin and fibronectin; and differentiate into ectodermal and mesodermal cell types;
- (c) differentiating the multipotent cells into one or more lineage committed cell types; and
- 5 (d) preserving and storing the differentiated cells for later retrieval.
27. A method for preparing cell preparations, comprising:
- (a) obtaining an epithelial tissue sample from a patient;
- (b) culturing cells dissociated from said tissue sample under conditions
- 10 wherein
- multipotent cells are expanded, which multipotent cells are characterized by the following: form non-adherent clusters in culture; are self renewing; express nestin and fibronectin; and differentiate into ectodermal and mesodermal cell types;
- 15 (c) differentiating the multipotent cells into one or more lineage committed cell
- types, wherein the conditions for differentiating the multipotent cells include
- modulating the plating conditions; and
- 20 (d) preserving and storing the differentiated cells for later retrieval.
28. The method of any of claims 25, 26 or 27, wherein the preserved cells are formulated in a pharmaceutically acceptable carrier, auxiliary or excipient.
- 25 29. The method of any of claims 25, 26 or 27, wherein the step of preserving the multipotent cells or differentiated cells includes cryogenic preservation.
30. A method for conducting a regenerative medicine business, comprising:
- (a) a service for accepting and logging in epithelial tissue samples from a
- 30 client;
- (b) a cell culture system for culturing cells dissociated from said tissue sample, which system provides conditions suitable for expanding

- multipotent cells in said sample, which multipotent cells are characterized by the following: form non-adherent clusters in culture; are self renewing; and differentiate into ectodermal and mesodermal cell types;
- 5 (c) a cell preservation system for preserving said multipotent cells for later retrieval on behalf of said client or other third party.
31. A method for conducting a regenerative medicine business, comprising:
- 10 (a) a service for accepting and logging in epithelial tissue samples from a client;
- (b) a cell culture system for culturing cells dissociated from said tissue sample, which system provides conditions suitable for expanding multipotent cells in said sample, which multipotent cells are characterized by the following: form non-adherent clusters in culture; are self renewing; and differentiate into ectodermal and mesodermal cell types;
- 15 (c) a cell differentiation system for differentiating said multipotent cells into one or more lineage committed cell types
- (d) a cell preservation system for preserving said lineage committed cells
- 20 for later retrieval on behalf of said client or other third party.
32. The method of claim 30 or 31, wherein said epithelial tissue is skin.
33. The method of claim 32, wherein said skin is selected from foreskin or skin
- 25 obtained from cosmetic surgery.
34. The method of claim 30 or 31, further including a billing system for billing the client or a medical insurance provider thereof.
- 30 35. A method for conducting a stem cell business, comprising:
- (i) identifying one or more agents which affect the proliferation, differentiation, or survival of multipotent stem cells;

- 5 (ii) conducting therapeutic profiling of agents identified in step (i), or
 analogous thereof, for efficacy and toxicity in animals; and
 (iii) formulating a pharmaceutical preparation including one or more
 agents identified in step (ii) as having an acceptable therapeutic
 profile.

10 36. The method of claim 35, wherein step (i) comprises contacting the
 multipotent stem cells with one or more small molecules and identifying
 those which affect the proliferation, differentiation, or survival of the
 multipotent stem cells.

15 37. The method of claim 35, wherein step (i) comprises contacting the
 multipotent stem cells with one or more extracellular proteins and identifying
 those which affect the proliferation, differentiation, or survival of the
 multipotent stem cells.

38. The method of claim 35, including an additional step of establishing a
 distribution system for distributing the pharmaceutical preparation for sale.

20 39. The method of claim 35 or 38, including establishing a sales group for
 marketing the pharmaceutical preparation.

25 40. A method of conducting a drug discovery business, comprising:
 (i) identifying one or more agents which affect the proliferation,
 differentiation, or survival of multipotent stem cells;
 (ii) licensing, to a third party, the rights for further drug development of
 agents identified in step (i) as able to affect the proliferation or
 differentiation of the multipotent stem cells.

30 41. A cellular composition of adult stem cells which (i) will proliferate in an in
 vitro culture, (ii) maintains the potential to differentiate to derivatives of

endoderm, mesoderm, and ectoderm tissues throughout the culture, and (iii) is inhibited from differentiation when cultured under proliferative conditions.

- 5 42. A cellular composition of adult stem cells which stem cells which (i) will proliferate in an in vitro culture for over one year, (ii) maintains a karyotype in which the chromosomes are euploid and not altered through prolonged culture, (iii) maintains the potential to differentiate to derivatives of endoderm, mesoderm, and ectoderm tissues throughout the culture, and (iv) is inhibited from differentiation when cultured under proliferative conditions.

10

43. A method of biasing differentiation of multipotent stem cells to a neuronal fate, comprising

- 15 (a) a proliferation phase,
(b) a pre-differentiation phase, and
(c) a differentiation phase.

1/47




Fig. 1A




Fig. 1B

2/47




Fig. 1C

3/47




Fig. 1D




Fig. 1E

4/47




Fig. 1F




Fig. 1G

5/47




Fig. 2

6/47




Fig. 3A




Fig. 3B

7/47




Fig. 3C




Fig. 3D

8/47





Fig. 4A



Fig. 4B

9/47

lating condition: FGF-2 + EGF



lating condition: Fetal Bovine Serum





Fig. 5

10/47




Fig. 6

11/47




Fig. 7A





Fig. 7B

12/47



13/47




Fig. 9A




Fig. 9B

14/47




Fig. 10

15/47



Fig. 11A




Fig. 11B

16/47



Fig. 11C




Fig. 11D



Fig. 11E




Fig. 12A




Fig. 12B




Fig. 12C



Fig. 12D

18/47




Fig. 13

19/47





Fig. 14

20/27



ALCIAN BLUE/ALIZARIN RED CO-STAINING REVEALS CALCIUM
ACCUMULATIONS WITHIN A LAYER OF CHONDROCYTIC PROTEOGLYCANS

Fig. 15

21/47





Fig. 16

22/47

FETAL CARDIAC ACTIN



GFP EXPRESSION



FETAL CARDIAC ACTIN
& HOECSHT




Fig. 17

23/47




Fig. 18

24/47




Fig. 19




Fig. 20




Fig. 21

27/47




Fig. 22

28/47






Fig. 23

29/47



bIII-TUBULIN



NF-M

Fig. 24

30/47





Fig. 25

31/47



S100



PERIPHRIN

Fig. 26

32/47




SMOOTH MUSCLE ACTIN

Fig. 27

33/47


RAT NEUROSPHERES



NESTIN

FIBRONECTIN


RAT OLFACTORY EPITHELIUM DERIVED MSCs



NESTIN

FIBRONECTIN

RAT SKIN DERIVED MULTIPOTENT STEM CELLS



NESTIN

FIBRONECTIN

Fig. 28

34/47


RELATIVE EXPRESSION OF TRANSCRIPTION FACTORS IN
SKIN-DERIVED MULTIPOTENT STEM CELLS VS. NEUROSPHERES

Fig. 29




Fig. 30

36/47





Fig. 31

37/47




Fig. 32

38/47

SONIC HEDGEHOG PROMOTES DIFFERENTIATION OF NEURALIZED SKIN DERIVED STEM CELLS






Fig. 33

39/47


WHAT TYPES OF NEURONS ARE GENERATED?




DβH



PERIPHERIN




NESTIN



TH

Fig. 34

40/47



MAP2

DIFFERENTIATION PHASE = 10 DAYS IN 1% SERUM + 50mM KCl

Fig. 35




Fig. 36

42/47





Fig. 37

43/47

**Fig. 38**

44/47

ROLE OF CELL DENSITY ON DIFFERENTIATION





Fig. 39

45/47

SCHWANN CELL DIFFERENTIATION						
	N2	S	F	S+F	S+F+H β	F+H β
HIGHD	-	+	+	+++	+++	+++
LOWD	-	++	+++	+++	+++	+++
<ul style="list-style-type: none">• SKIN DERIVED STEM CELLS DIFFERENTIATE INTO CELLS EXPRESSING LATE SCHWANN CELL MARKERS WITH APPROPRIATE MORPHOLOGY• cAMP ELEVATION PROMOTES SCHWANN CELL DIFFERENTIATION						

Fig. 40

46/47




Fig. 41

SKPs: Slide #1				SKPs: Slide #2				Stem cells from Olf. epithelium			
Field #	NO. of Cells i.e. nuclei/field	P75(lev)		Field #	NO. of Cells i.e. nuclei/field	P75(lev)		Field #	NO. of Cells i.e. nuclei/field	P75(lev)	
#1	149	0		#26	6	0		#1	310		
#2	133	0		#27	11	0		#2	307		
#3	176	3		#28	23	0		#3	322		
#4	228	5		#29	5	0		#4	334		
#5	229	2		#30	8	0		#5	430		
#6	132	2		#31	7	0		#6	290		
#7	221	2		#32	5	0		#7	333		
#8	191	2		#33	7	0		#8	315		
#9	212	2		#34	11	1		#9	326		
#10	187	0		#35	29	3		#10	223		
				#36	10	1		#11	524		
				#37	9	0		#12	470		
				#38	16	0					
				#39	23	0					
				#40	7	0					
				#41	8	0					
				#42	10	0					
				#43	12	0					
				#44	5	0					
				#45	4	0					
				#46	7	0					
				#47	21	0					
				#48	25	0					
				#49	40	0					
				#50	11	0					
					</						

Fig. 42